



Genome-wide association analysis identifies ancestry-specific genetic variation associated with acute response to metformin and glipizide in SUGAR-MGH

Josephine H. Li^{1,2,3,4} · Laura N. Brenner^{1,3,4,5} · Varinderpal Kaur^{1,2,3} · Katherine Figueroa^{1,3} · Philip Schroeder^{1,2,3} · Alicia Huerta-Chagoya^{1,2,3} · MAGIC Investigators · Diabetes Prevention Program (DPP) Research Group · Miriam S. Udler^{1,2,3,4} · Aaron Leong^{1,2,3,4,6} · Josep M. Mercader^{1,2,3,4} · Jose C. Florez^{1,2,3,4}

Received: 14 December 2022 / Accepted: 6 March 2023

© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023

Abstract

Aims/hypothesis Characterisation of genetic variation that influences the response to glucose-lowering medications is instrumental to precision medicine for treatment of type 2 diabetes. The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH) examined the acute response to metformin and glipizide in order to identify new pharmacogenetic associations for the response to common glucose-lowering medications in individuals at risk of type 2 diabetes.

Methods One thousand participants at risk for type 2 diabetes from diverse ancestries underwent sequential glipizide and metformin challenges. A genome-wide association study was performed using the Illumina Multi-Ethnic Genotyping Array. Imputation was performed with the TOPMed reference panel. Multiple linear regression using an additive model tested for association between genetic variants and primary endpoints of drug response. In a more focused analysis, we evaluated the influence of 804 unique type 2 diabetes- and glycaemic trait-associated variants on SUGAR-MGH outcomes and performed colocalisation analyses to identify shared genetic signals.

Results Five genome-wide significant variants were associated with metformin or glipizide response. The strongest association was between an African ancestry-specific variant (minor allele frequency [MAF_{Afr}]=0.0283) at rs149403252 and lower fasting glucose at Visit 2 following metformin ($p=1.9\times 10^{-9}$); carriers were found to have a 0.94 mmol/l larger decrease in fasting glucose. rs111770298, another African ancestry-specific variant (MAF_{Afr} =0.0536), was associated with a reduced response to metformin ($p=2.4\times 10^{-8}$), where carriers had a 0.29 mmol/l increase in fasting glucose compared with non-carriers, who experienced a 0.15 mmol/l decrease. This finding was validated in the Diabetes Prevention Program, where rs111770298 was associated with a worse glycaemic response to metformin: heterozygous carriers had an increase in HbA_{1c} of 0.08% and non-carriers had an HbA_{1c} increase of 0.01% after 1 year of treatment ($p=3.3\times 10^{-3}$). We also identified associations between type 2 diabetes-associated variants and glycaemic response, including the type 2 diabetes-protective C allele of rs703972 near *ZMIZ1* and increased levels of active glucagon-like peptide 1 (GLP-1) ($p=1.6\times 10^{-5}$), supporting the role of alterations in incretin levels in type 2 diabetes pathophysiology.

Conclusions/interpretation We present a well-phenotyped, densely genotyped, multi-ancestry resource to study gene–drug interactions, uncover novel variation associated with response to common glucose-lowering medications and provide insight into mechanisms of action of type 2 diabetes-related variation.

Data availability The complete summary statistics from this study are available at the Common Metabolic Diseases Knowledge Portal (<https://hugeamp.org>) and the GWAS Catalog (www.ebi.ac.uk/gwas/, accession IDs: GCST90269867 to GCST90269899).

Josephine H. Li, Laura N. Brenner and Varinderpal Kaur contributed equally to this work.

Josep M. Mercader and Jose C. Florez jointly directed this work.

Members of the MAGIC Consortium and the DPP Research Group are included as collaborators and listed in the electronic supplementary material (ESM) text.

Extended author information available on the last page of the article

Keywords Genetics · Genome-wide association study · Glipizide · Incretin · Metformin · Multi-ancestry · Pathophysiology · Pharmacogenetics · Sulfonylurea · Type 2 diabetes

Research in context

What is already known about this subject?

- Treatment of type 2 diabetes is currently algorithmic and does not consider an individual's underlying genetics or the disease pathophysiology that might benefit from a tailored intervention
- Genome-wide association studies (GWAS) have uncovered genetic loci influencing metformin and sulfonylurea response but were largely performed in European populations with established disease

What is the key question?

- Can a genome-wide approach identify new pharmacogenetic associations and generate insight into the functional relevance of known genetic risk factors for type 2 diabetes in a multi-ethnic acute drug perturbation study of individuals at increased risk of type 2 diabetes?

What are the new findings?

- We identified novel genomic regions associated with acute metformin and glipizide response at genome-wide significance
- Several top findings were more common in participants of African ancestry, underscoring the importance of studying non-European populations
- Established type 2 diabetes and glycaemic trait loci were associated with differences in incretin levels in SUGAR-MGH with evidence of colocalisation; these findings provide further insight into incretin physiology as a potential mechanism by which these variants influence type 2 diabetes risk, with implications for use of incretin-based medication

How might this impact on clinical practice in the foreseeable future?

- Our study provides initial proof of concept for considering ancestry-specific genetic variation in the choice of pharmacotherapy for type 2 diabetes and advances precision medicine

Abbreviations

AOC	Area over the curve
DPP	Diabetes Prevention Program
EAF	Effect allele frequency
gePS	Global extended polygenic score
GLP-1	Glucagon-like peptide 1
GWAS	Genome-wide association study
LD	Linkage disequilibrium
MAF	Minor allele frequency
PC	Principal component
PP	Posterior probability
pPS	Process-specific polygenic score
SUGAR-MGH	Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans
V1	Visit 1
V2	Visit 2

Introduction

Treatment of type 2 diabetes currently follows a standard algorithm that begins with metformin [1], but involves the

trial and error of additional drug regimens as the disease progresses. The choice of agent is based on several considerations, including an individual's comorbidities, the drug's side effect profile and costs of the therapy, but does not include information about the molecular target of the agent or genetic factors that might predict response or development of adverse effects [2]. The understanding of who responds best to each medicine is instrumental to furthering and optimising care of patients with diabetes.

Large-scale genome-wide association studies (GWAS) have identified over 700 genetic variants influencing type 2 diabetes risk and glycaemic traits. Data on how genetic variation influences response to glucose-lowering medications are starting to emerge. In individuals with established type 2 diabetes, GWAS have revealed novel loci for glycaemic response to metformin [3, 4]. With respect to sulfonylureas, candidate gene studies have uncovered genetic predictors of glycaemic response [5, 6] as well as sulfonylurea-induced hypoglycaemia [7, 8]. Recently, a GWAS of sulfonylurea response identified two independent loci associated with HbA_{1c} reduction [9]. Since the majority of pharmacogenetic studies have been conducted in those

with established type 2 diabetes, a genome-wide approach evaluating the response to metformin and sulfonylureas in a population at risk for developing type 2 diabetes has not previously been carried out.

Moreover, the functional relevance of many type 2 diabetes and glycaemic loci is not fully understood. The mechanisms leading to the development of type 2 diabetes are complex, both intrinsic and extrinsic to the beta cell [10]. For instance, an intronic variant in *TCF7L2* is the strongest common genetic risk factor for type 2 diabetes [11], yet multiple mechanisms have been proposed, including reduced beta cell mass, diminished insulin secretion and alterations in the incretin response [12]. In the Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH), we previously observed that an impaired incretin effect may contribute to the increased risk of type 2 diabetes in carriers of the high-risk allele at *TCF7L2* [5, 13].

In this study, we applied a genome-wide approach to comprehensively identify novel genetic predictors of acute metformin and glipizide response in individuals at risk of type 2 diabetes but naive to these medications. We examined the effects of known genetic variants associated with type 2 diabetes and glycaemic traits across all outcomes in SUGAR-MGH to gain further insights into the mechanisms by which they confer increased risk of type 2 diabetes or glycaemic dysregulation. Overall, we present and make available a resource for studying how genetic variation influences the biochemical response to two common glucose-lowering agents.

Methods

Study design and participants SUGAR-MGH is a pharmacogenetic study in which 1000 individuals who were naive to type 2 diabetes medications received a single-dose glipizide challenge and a short course of metformin [5, 14]. Participants at risk for diabetes, defined as participants with the metabolic syndrome, obesity, a history of gestational diabetes, a history of polycystic ovarian syndrome or a family history of type 2 diabetes, were preferentially enrolled. The rationale for selecting an at-risk population was twofold: (1) a recruitment strategy to increase participation; and (2) individuals with relatively intact beta cell function may have a more robust response to sulfonylureas and metformin. Figure 1 summarises the study design, which is described in detail in the electronic supplementary material (ESM) Methods. The study has been registered on [ClinicalTrials.gov](https://clinicaltrials.gov) (NCT01762046) and is approved by the Mass General Brigham Human Research Committee Institutional Review Board (IRB).

Genotyping and imputation One thousand samples underwent genome-wide genotyping on the Multi-Ethnic

Genotyping Array (Illumina, San Diego, CA, USA), which covers over 1.7 million genetic markers. A three-step quality control protocol was applied using PLINK 1.9 [15]. This included two stages of variant removal and an intermediate stage of sample exclusion. Variants were filtered for minor allele frequency (MAF) <0.01, low call rate <95% and failure to meet Hardy–Weinberg equilibrium within each self-described ancestry group ($p < 5 \times 10^{-7}$). Samples were excluded for sex discrepancies, close relatedness (pairs with π^{\wedge} [pi-hat] ≥ 0.125 , from which we removed the individual with the highest proportion of missingness) and call rate <98%. Phasing was performed using SHAPEIT2 [16]. Imputation was performed with the Michigan Imputation Server using the TOPMed reference panel [17]. After post-imputation quality control, excluding variants with imputation $R^2 < 0.8$ and $MAF < 0.005$, ~12 million variants were available for analyses in 890 individuals. Genome annotations were generated using the GRCh38 assembly.

Endpoints of metformin and glipizide response As previously described [14], the primary endpoint of metformin response was defined as the fasting glucose at Visit 2 (V2), adjusted for fasting glucose at Visit 1 (V1). For the primary outcome of glipizide response, we selected the following closely related endpoints: insulin peak adjusted for baseline insulin, glucose trough adjusted for baseline glucose and time to glucose trough. We identified secondary outcomes of metformin and glipizide response based on measurements taken during the glipizide challenge and the 75 g OGTT following metformin (ESM Table 1), including insulin, incretin and homeostasis model assessments.

Genome-wide association analysis We performed genome-wide association analyses to assess the role of genetic variation in the acute response to metformin and glipizide. Multiple linear regression using an additive model tested for association between genetic variants and the primary endpoints, implemented using SNPTEST v2.5.4. Analyses were adjusted for age, sex, BMI and the first ten ancestry principal components (PCs) to account for population stratification. Quantitative traits were rank-inverse normalised to avoid spurious associations driven by outliers or skewed distributions and β estimates reflect rank-inverse normalisation. When relevant, we adjusted for the baseline trait at V1. Genome-wide significance was set at $p < 5 \times 10^{-8}$ and an experiment-wide threshold was set at $p < 2.5 \times 10^{-8}$, accounting for two drugs. Manhattan and quantile–quantile plots were produced with R (version 4.0) [18], and regional association plots were generated in LocusZoom [19] using the linkage disequilibrium (LD) reference panel for the ancestry that had the highest allele frequency for each variant.




Fig. 1 Study schema. **(a)** We recruited 1000 individuals at risk of developing type 2 diabetes. **(b)** At V1, participants had their vital signs monitored, provided whole blood for DNA and underwent fasting measurements. Individuals with a fasting blood sugar >4.4 mmol/l received a dose of 5 mg of glipizide orally, followed by additional measurements. **(c)** After a 5 day wash-out period,

participants received three doses of metformin of 500 mg. **(d)** At V2, participants returned for the final (fourth) dose of metformin and a 75 mg OGTT. **(e)** We performed genome-wide genotyping, constructed phenotypes of drug response and performed a GWAS, in order to **(f)** identify genotypes associated with outcomes of drug response. MTF, metformin; SU, sulfonylurea

In an exploratory analysis, we tested for the association of variants with the pre-defined secondary drug outcomes and assessed findings that reached both genome-wide significance for at least one trait, and suggestive significance threshold of $p < 1 \times 10^{-6}$ for another trait. For top variants of interest, we examined their association with glucose and insulin curves during the glipizide challenge and the OGTT following metformin. Multiple linear regression assessed for differences in outcomes by genotype groups, adjusted for similar covariates.

We also assessed the association between previously reported genome-wide significant loci for type 2 diabetes and quantitative glycaemic phenotypes and all available traits in SUGAR-MGH. We evaluated 429 genetic variants associated with type 2 diabetes [20, 21] and 375 genetic variants associated with glycaemic traits [22]. We used an r^2 threshold of 0.5 to prune variants based on LD, using the full 1000 Genomes as a reference panel and LDlink [23], resulting in 563 independent effective markers. Based on their higher prior probability for glycaemic associations, we did not demand genome-wide significance in these analyses. While we corrected for the number of variants, we did not correct for the number of traits in SUGAR-MGH because they are highly correlated. The resultant threshold ($p < 8.9 \times 10^{-5}$ [0.05/563]) was used to prioritise associations for which we proceeded with colocalisation analyses of the SUGAR-MGH trait and the relevant type 2 diabetes/glycaemic trait in order to confirm the presence of shared genetic risk factors (ESM Methods) [24].

We generated weighted global extended polygenic scores (gePSs) for type 2 diabetes, fasting glucose, fasting insulin and HbA_{1c}, based on summary statistics from published GWAS of type 2 diabetes and glycaemic traits [20–22]. To construct the gePS, we used PRS-CS using auto as a global shrinkage parameter [25]. We constructed five process-specific polygenic scores (pPSs) derived from physiologically driven clusters [26]. We tested these scores against the primary endpoints of metformin and glipizide response and set an experiment-wide significance threshold of $p < 0.003$ to account for multiple comparisons (two drugs \times nine polygenic scores). We adjusted for the same covariates as in the primary GWAS.

Replication of metformin response variants in the Diabetes Prevention Program We attempted to replicate the genome-wide significant variants associated with metformin response in the Diabetes Prevention Program (DPP), a multicentre randomised controlled trial that evaluated the impact of intensive lifestyle modification and pharmacologic intervention on development of type 2 diabetes in high-risk individuals [27, 28]. A GWAS of metformin response, defined as diabetes incidence and change in quantitative traits (fasting glucose, 2 h glucose on OGTT, HbA_{1c}, fasting insulin,

insulin sensitivity index and weight), has been completed in the DPP [29]. The full study details of the GWAS completed in the DPP are described in the ESM Methods. For the replication of SUGAR-MGH findings, we tested the association of our top metformin findings with the 1 year change (follow-up minus baseline) in fasting glucose and HbA_{1c} in the metformin treatment arm only. Multiple linear regression using an additive model was performed, adjusting for baseline trait, age, sex and ten ancestry PCs. In the published GWAS completed in the DPP, a sensitivity analysis showed that GWAS findings did not change with additional adjustment for BMI, so it was not included in the model [29]. To account for multiple testing, we set a replication significance threshold based on two outcomes and the number of variants tested in replication.

Results

Participant characteristics Baseline demographics of the 890 participants with complete GWAS data are summarised (ESM Table 2). Approximately 53% of participants were female, the mean age was 47 years and 37% of participants self-reported as non-white. The mean BMI was 30.2 kg/m² and mean fasting glucose was 5.14 mmol/l, consistent with a population at risk for requiring future treatment of type 2 diabetes. The HOMA-B score at baseline was 91.3, comparable to that observed in healthy individuals without type 2 diabetes and normal fasting glucose [30, 31]. Of the 890 participants with genetic data, 20 participants did not receive the glipizide challenge due to a low baseline fasting glucose and 298 terminated the challenge early for hypoglycaemia, in accordance with study protocol.

Association of genetic variation with primary outcomes of drug response We identified five genome-wide significant variants associated with primary endpoints of acute metformin and glipizide response, four of which met experiment-wide significance of $p < 2.5 \times 10^{-8}$ (Table 1). Three variants (rs149403252, rs111770298 and rs117207651) were associated with metformin response, as measured by fasting glucose at V2, adjusted for fasting glucose at V1; two variants (rs9954585 and rs150628520) were associated with glipizide response, as measured by the time to glucose trough. For each of the five variants, the allele counts by self-reported race/ethnicity are listed in ESM Table 3.

Among the variants associated with metformin response at genome-wide significance, rs149403252 ($MAF_{Afr} = 0.0283$, $\beta = -1.3$, $p = 1.9 \times 10^{-9}$) is an African ancestry-specific variant located in chromosome 3 near *ERC2* (ESM Fig. 1a). Carriers of the T effect allele had a lower fasting glucose at V2, adjusted for baseline glucose, indicating that they had an

Table 1 Genome-wide significant variants ($p < 5 \times 10^{-8}$) associated with primary endpoints of acute metformin or glipizide response in SUGAR-MGH

rsID	Chr	Position ^a	Nearest gene	NEA	EA	EAF	N	Genotype counts ^b	AFR ^c	AMR ^c	EAS ^c	EUR ^c	SAS ^c	Trait	β^d	p value
Metformin response																
rs149403252	3	55883717	ERC2	G	T	0.006	805	796/9/0	0.0283	0.0018	0	<0.0001	0.0002	Fasting glucose at V2, adjusted for V1	-1.3	1.9×10^{-9}
rs111770298	2	28307503	BABAM2/FOSL2	A	G	0.013	805	784/21/0	0.0536	0.0048	0	0.0001	0.0002	Fasting glucose at V2, adjusted for V1	0.8	2.4×10^{-8}
rs117207651	16	82250950	MPHOSPH6	T	C	0.009	805	794/11/0	0.0030	0.0082	0	0.0158	0.0008	Fasting glucose at V2, adjusted for V1	-1.0	4.5×10^{-8}
Glipizide response																
rs9954585	18	56245092	TXNLI	C	T	0.013	550	536/14/0	0.0602	0.0052	0.0002	0.0010	0.0008	Time to reach glucose trough at V1	-1.5	7.0×10^{-9}
rs150628520	4	187296094	FA7I	A	G	0.009	550	543/7/0	0.0020	0.0068	0.0002	0.0114	0.0025	Time to reach glucose trough at V1	1.7	9.8×10^{-9}

^aGRCh38 assembly^bReported as the number of individuals carrying 0, 1 or 2 copies of the effect allele. For all imputed variants, fractional alleles were converted to hard calls for calculation of genotype counts^cAncestry-specific allele frequencies as reported in gnomAD version 3.1.2^d β estimates are rank-inverse normalised. A negative β when evaluating metformin response implies that the effect allele is associated with an enhanced response to metformin, i.e. lower fasting glucose following metformin exposure. A negative β when evaluating glipizide response implies that the effect allele is associated with an enhanced response to glipizide, i.e. shorter time to reach glucose trough following glipizide exposure

AFR, African; AMR, admixed American; Chr, chromosome; EA, effect allele; EAF, effect allele frequency; EAS, East Asian; EUR, European; NEA, non-effect allele; rsID, reference SNP cluster identifier; SAS, South Asian

enhanced metformin response. This was particularly apparent when examining the change in fasting glucose (ESM Fig. 1b), in which heterozygous individuals had a decrease of 1.1 mmol/l after four doses of metformin compared with a decrease of 0.12 mmol/l in non-carriers (β of difference = -0.94 mmol/l [$p=1.1\times 10^{-6}$]). During the OGTT following metformin, heterozygous individuals had lower insulin AUC ($p=0.005$) despite statistically similar glucose AUC. Another African ancestry-specific genetic variant influencing metformin response was rs111770298 (MAF_{Afr} = 0.0536, $\beta=0.8$ [$p=2.4\times 10^{-8}$]), located in an intron of *BABAM2* in chromosome 2 (Fig. 2). Carriers of the G allele had a reduced metformin response, as evidenced by a higher fasting glucose at V2, adjusted for baseline glucose at V1. We calculated that whereas individuals homozygous for the A (common) allele experienced a 0.15 mmol/l decrease in fasting glucose after metformin, heterozygous individuals had a 0.29 mmol/l increase (β of difference = 0.43 mmol/l [$p=9.4\times 10^{-7}$]). Finally,

rs117207651 near *MPHOSPH6* was associated with a better response to metformin (ESM Fig. 2): whereas TT individuals experienced a 0.13 mmol/l decrease in fasting glucose after metformin, TC individuals had a greater decrease of 0.50 mmol/l (β of difference = -0.50 mmol/l [$p=1.8\times 10^{-4}$]).

We attempted validation of our top three variants associated with metformin response in the DPP, a randomised controlled trial of lifestyle intervention or pharmacologic therapy (metformin) conducted in individuals with impaired glucose tolerance at high risk for developing type 2 diabetes. The outcomes examined were changes in fasting glucose and HbA_{1c} after 1 year of follow-up. We set a replication significance threshold of $p<0.008$ (two outcomes \times three variants). Results are summarised in ESM Table 4. rs111770298 was significantly associated with worse metformin response, where heterozygous carriers experienced a 0.08% increase in the 1 year change in HbA_{1c} after 1 year of metformin treatment, compared with an increase of 0.01% in non-carriers




Fig. 2 (a) Regional association plot of rs111770298. (b) Box plot illustrating mean change in fasting glucose (V2 minus V1) by rs111770298 genotype

($p=3.3\times 10^{-3}$), thus confirming our findings in SUGAR-MGH. For rs149403252 and rs117207651, we did not replicate our findings in the DPP.

For the glipizide challenge, the strongest glipizide-associated variant was rs9954585, near *TXNLI* in chromosome 18 (ESM Fig. 3). Being a carrier of the T allele was associated with a shorter time to glucose trough (EAF=0.013, $\beta=-1.5$, $p=7.0\times 10^{-9}$). In addition, rs150628520, a low-frequency variant near *FAT1* in chromosome 4 (ESM Fig. 4a), was associated with increased time to glucose trough, consistent with a diminished glipizide response (EAF=0.009, $\beta=1.7$, $p=9.8\times 10^{-9}$). In agreement with this, carriers of the G allele had a significantly decreased cumulative drop in glucose, measured by glucose area over the curve (AOC) (ESM Fig. 4b, $p=0.004$), as well as a decreased insulin AUC (ESM Fig. 4c, $p=0.006$).

Association of genetic variation with secondary outcomes of drug response Beyond the primary outcomes, we examined associations reaching genome-wide significance ($p<5\times 10^{-8}$) for either the primary or secondary outcomes (ESM Table 1). We curated a list of variants that were additionally associated with at least one other secondary outcome at a suggestive $p<1\times 10^{-6}$ and in consistent direction of effect (e.g. both associations pointing toward enhanced metformin response). ESM Table 5 describes the resultant set of markers that met these criteria and were therefore considered to be likely true associations with metformin or glipizide response. Notably, two of the primary GWAS findings (rs150628520 and rs111770298) were also associated with secondary outcomes (ESM Table 5).

Evaluation of known type 2 diabetes and glycaemic variation and polygenic scores in SUGAR-MGH We next focused on assessing the pharmacological response to variants previously associated with type 2 diabetes and quantitative glycaemic traits. Within the associations meeting our screening threshold ($p<8.9\times 10^{-5}$) for colocalisation analysis, we were able to confirm through colocalisation analyses that ten of them share the same genetic signal between a SUGAR-MGH outcome and type 2 diabetes/glycaemic traits with a posterior probability (PP) of $\geq 75\%$ (ESM Table 6). As an example, we found that the type 2 diabetes-protective C allele of rs703972 near *ZMIZ1* was associated with increased levels of active glucagon-like peptide 1 (GLP-1) ($p=1.6\times 10^{-5}$), with high evidence of colocalisation (PP=90.3%, Fig. 3a–c).

When we evaluated the influence of polygenic scores on drug response, we confirmed our previously reported nominal association between a higher type 2 diabetes polygenic score and greater glucose AOC, representing a greater cumulative drop in glucose following glipizide ($p=0.02$) [32]. In addition, we observed an association between the fasting glucose gePS and the primary outcome for metformin

response meeting experiment-wide significance ($p=0.002$): after adjusting for baseline glucose, individuals with higher fasting glucose gePS had a 0.03 mmol/l lower drop in fasting glucose after metformin per SD increase in polygenic score, consistent with a worse metformin response. In a subgroup analysis, this was found to be driven by individuals who began the study with a fasting glucose over 5 mmol/l, who experienced a mean drop of 0.07 mmol/l ($p=0.04$). No associations between any of the pPSs and metformin or glipizide response met experiment-wide significance (ESM Table 7).

Discussion

SUGAR-MGH is a pharmacogenetic resource for characterising genetic influences on pharmacological perturbations relevant to type 2 diabetes. In prior work, SUGAR-MGH has contributed to the understanding of the influence of *TCF7L2* and *CYP2C9*, as well as a restricted-to-significant (i.e. using only genome-wide significant variants) type 2 diabetes polygenic risk score, on drug response [5, 8, 32]. With the completion of genome-wide genotyping, we report new genetic associations with acute metformin and sulfonylurea response in an ancestrally diverse population at risk for type 2 diabetes and naive to commonly prescribed glucose-lowering medications.

We identified three variants that were significantly associated with acute response to metformin, of which two were African ancestry-specific variants. The strongest association was between rs149403252, an intronic variant located in *ERC2*, and lower fasting glucose following metformin, but unfortunately this finding did not replicate. *ERC2* encodes a protein in the CAZ-associated structural protein (CAST) family, which has been implicated in the calcium-dependent exocytosis of neurotransmitters [33]; one family member is present in pancreatic beta cells and may be involved in the regulation of insulin secretion [34]. More robustly, rs111770298 was associated with both a reduced response to metformin in SUGAR-MGH, as measured by a higher fasting glucose after metformin, and a rise in HbA_{1c} in independent replication in the DPP. rs111770298 is an intronic variant located near *BABAM2* and *FOSL2*, the latter of which has been shown to promote leptin gene expression in mouse adipocytes [35]. Rare coding and common variants in or near *FOSL2* are associated with lower triglyceride levels [36]. In the Type 2 Diabetes Knowledge Portal [36], this variant has a nominal association with diastolic blood pressure. Fine-mapping analyses, phenome-wide association analyses and functional experiments will be needed to confirm the implication of these loci in metformin response.

We uncovered several promising variants of interest for glipizide response. T allele carriers at rs9954585 have a shorter time to glucose trough, indicating a more robust




Fig. 3 (a) Colocalisation plot showing that rs703972 near *ZMIZ1* colocalises with active GLP-1 and type 2 diabetes risk. (b, c) LocusZoom plots of association of rs703972 with (b) type 2 diabetes and (c) active GLP-1. (d) Change in total and (e) active GLP-1

by rs703972 at V2 during OGTT. abf, approximate Bayes factor; T2D_DIAMANTE_EUR, GWAS results in European population from Diabetes, Meta-Analysis Trans-Ethnic Consortium

response to glipizide. G allele carriers at rs150628520 near *FAT1* appear to have an attenuated response to glipizide, having not only an increased time to glucose trough but also a more gradual slope to glucose trough. We also note that the presence of concordant associations across multiple primary and secondary outcomes for glipizide response provides support for our genetic findings. However, it is unclear whether the observed differences by genotype are due to a decrease in glipizide action or impairment in glipizide absorption. To further elucidate the mechanisms responsible for these effects, future directions include quantifying glipizide drug levels, and comparing carriers and non-carriers at these loci.

We tried to characterise the biological mechanisms of known type 2 diabetes and glycaemic loci by leveraging the phenotypic outcomes constructed in this physiological study. We identified established genome-wide significant type 2 diabetes and glycaemic variation that met our screening criteria for association with highly correlated traits in SUGAR-MGH and proceeded with colocalisation analysis to confirm the presence of shared genetic risk factors. We demonstrated that the protective C allele of rs703972 near *ZMIZ1* was associated with increased levels of active GLP-1. Interestingly, *ZMIZ1* has been previously reported to play a role in regulation of

beta cell function, with expression of *ZMIZ1* reducing insulin secretion [37]. Thus, an augmented incretin response may explain how C allele carriers are able to mitigate their type 2 diabetes risk. Incretins have been implicated in the pathophysiology of type 2 diabetes; however, it is unknown whether the incretin effect is impaired due to a reduction in functional beta cell mass or due to a defect in incretin action leading to resistance [38]. Our findings provide support for altered incretin physiology in the pathogenesis of type 2 diabetes and shed additional insight on a potential mechanism underlying the effect of the *ZMIZ1* variant. This example demonstrates that our research can be used to determine endophenotypes of already known genetic associations and can serve as a useful resource for characterisation of future associations.

Previously, we reported that a higher type 2 diabetes polygenic score of 65 variants was associated with several measures of glipizide response at nominal significance [32], but we did not identify any associations with phenotypes of metformin response. With the availability of genome-wide genotyping and access to full summary statistics from larger meta-analyses for type 2 diabetes and glycaemic traits, we expanded our analysis to incorporate large numbers of sub-significant variants across the genome. With a type 2 diabetes gePS, we confirmed the

previous association between a higher genetic burden for type 2 diabetes and greater glucose AOC, indicating an enhanced response to glipizide at this early stage of dysglycaemia. This is consistent with the findings of Dennis et al in the A Diabetes Outcome Progression Trial (ADOPT), in which participants with a phenotypically defined severe insulin-deficient diabetes demonstrated a robust early response to sulfonylureas, which was attenuated as their beta cell function deteriorated over time [39]. Moreover, we found that individuals with a greater burden of risk variants for higher fasting glucose, possibly representing a genetic susceptibility for lower beta cell function, had a diminished response to metformin. Our ability to detect this pharmacogenetic association was likely bolstered by the vast increase in the number of variants included in the polygenic score and may have clinical implications for the effectiveness of metformin as a first-line therapy in those genetically predisposed to fasting dysglycaemia. While we hypothesised that physiologically derived clusters related to the drug's mode of action may have an influence on the acute drug response (i.e. association between beta cell function clusters and glipizide response), we did not detect associations with primary outcomes of metformin or glipizide response, possibly due to lower statistical power of the pPSs, which comprise a smaller number of variants. Given the increasing availability of genotype information, future studies are needed to validate the utility and predictive value of polygenic scores for drug response.

Our study is the first GWAS of acute metformin and glipizide response including participants at risk of type 2 diabetes from multiple ancestries. In contrast to existing type 2 diabetes pharmacogenetic GWAS performed in European populations [3, 4, 9], over a third of SUGAR-MGH participants were of non-European descent. The value of analysing cohorts that span multiple ancestries is exemplified by the identification of novel associations in genetic variants that are more prevalent in non-European populations. Several of our genome-wide significant findings (rs149403252 near *ERC2*, rs9954585 near *TXNLI* and rs111770298 near *BABAM2/FOSL2*) had minor allele frequencies that were common to low frequency in African populations and rare in European populations. Associations near these genes have not previously been identified as related to type 2 diabetes risk or response to glucose-lowering medications, which may be due to the dearth of studies in non-European populations. Understanding the impact of such ancestry-specific variants may guide treatment decisions for type 2 diabetes in these population subgroups in the future, but also provide drug targets suitable for all ancestries. One major barrier to translating ancestry-specific variants to their function is the lack of ancestry-specific genetic and genomic data. For instance, the Genotype-Tissue Expression (GTEx) project largely contains individuals with European ancestry [40], limiting our ability to characterise the effects of genome-wide significant variants not present or at low frequency in Europeans on the transcriptome across human tissues. Similarly, the lack of phenome-wide association data

on diverse ancestries hinders follow-up of identified variants. Expansion of existing datasets to include non-European populations will be valuable for linking pharmacogenetic associations to functional mechanisms.

Given the global dearth of pharmacogenomic GWAS, especially those conducted in non-European populations, one major challenge of this work was identifying a suitable replication venue. Due to the unique characteristics of this study examining acute drug response, no comparable replication venue was readily available. However, we sought replication in the DPP, a study of individuals with prediabetes who received longitudinal metformin exposure. We illustrated that the influence of rs111770298 on 1 year change in HbA_{1c} validated our findings for fasting glucose in SUGAR-MGH, with a consistent direction of effect on metformin response. However, we did not observe a differential impact of this same variant on 1 year change in fasting glucose in the DPP. One explanation is that the variant's effect on fasting glucose might be more pronounced and better detected initially in the acute setting; perhaps in the DPP, the long-term effect is better captured by average blood glucose levels as measured by change in HbA_{1c}.

We also recognise that our study examined those at risk of type 2 diabetes, and it is unclear whether our findings would have the same magnitude of effect in people with overt or long-standing type 2 diabetes, as disease stage may affect the metabolic state of a person who carries the same genetic profile. For example, variants in drug transporter genes that influence response to metformin in healthy individuals [41] were not found to affect HbA_{1c} in people with type 2 diabetes [42]. Another limitation is that the study design did not incorporate a baseline OGTT, which limited our ability to assess the impact of metformin on a dynamic glucose challenge. This was due to the financial and time constraints of enrolling participants for an additional OGTT. A final limitation is that our sample size was small for measurements of incretin levels, which restricted our ability to detect additional findings relevant to incretin physiology.

In summary, we identified novel genetic variation in a multi-ethnic human drug perturbation study which requires validation in ancestry-specific cohorts but has the potential to influence the selection of glucose-lowering medications in specific populations. We demonstrated the utility of our pharmacogenetic resource for understanding the underlying mechanisms of known genetic variation for type 2 diabetes and glycaemic traits. Beyond the primary drug endpoints, we created a public resource to permit the organisation and sharing of genetic association results across a wide variety of traits in SUGAR-MGH, which can be used as a validation cohort for future pharmacogenetic discoveries by others as well as for functional characterisation of newly identified genes implicated in the pathogenesis of type 2 diabetes.

Supplementary Information The online version contains peer-reviewed but unedited supplementary material available at <https://doi.org/10.1007/s00125-023-05922-7>.

Acknowledgements We would like to thank J. Del Rio (freelance graphic designer, Cambridge, MA, USA) for his support with Fig. 1 generation. Portions of this study were previously presented as an oral presentation at the 81st Virtual Scientific Sessions of the American Diabetes Association, 25–29 June 2021.

Data availability The complete summary statistics from this study will be deposited and made available at the Common Metabolic Diseases Knowledge Portal (<https://hugeamp.org>) and the GWAS Catalog (www.ebi.ac.uk/gwas/, accession IDs: GCST90269867 to GCST90269899) following article publication. Related study documents, including the original study protocol and informed consent forms, are available [14]. Additional data requests should be sent by email to the corresponding author.

Funding This work was conducted with support from National Institutes of Health/NIDDK awards R01 GM117163, R01 DK088214, R03 DK077675 and P30 DK036836; from the Joslin Clinical Research Center from its philanthropic donors; and from the Harvard Catalyst: the Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH Awards M01-RR-01066, 1 UL1 RR025758-04 and 8UL1TR000170-05, and financial contributions from Harvard University and its affiliated academic healthcare centres). JHL received individual support from NIH T32DK007028 and NIDDK K23DK131345. LNB is supported by NIDDK K23DK125839. MSU is supported by NIDDK K23DK114551. AL is supported by grant 2020096 from the Doris Duke Charitable Foundation and the American Diabetes Association grant 7-22-ICTSPM-23. JMM is supported by American Diabetes Association Innovative and Clinical Translational Award 1-19-ICTS-068, American Diabetes Association grant #11-22-ICTSPM-16, and by NHGRI U01HG011723. JCF is supported by NHLBI K24HL157960.

Authors' relationships and activities The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.

Contribution statement All authors took part in designing the experiments presented in this manuscript. VK, LNB, MSU, AL and JCF recruited participants in SUGAR-MGH. VK supervised participant recruitment, data collection, and IRB review and approval, and performed DNA extractions and managed GWAS genotyping. Quality control, imputation of the genetic data and GWAS analyses were performed by JMM. JHL, LNB, VK, KF, PS, AH-C and JMM performed follow-up of GWAS data analysis. JHL, LNB, VK, JMM and JCF contributed to the interpretation of the results. JHL, LNB, VK and JMM wrote and prepared the manuscript. All authors revised and approved the final manuscript. JMM and JCF jointly supervised this study. JCF is the guarantor of this work.

References

- Davies MJ, D'Alessio DA, Fradkin J et al (2018) Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 41(12):2669–2701. <https://doi.org/10.2337/dci18-0033>
- Chung WK, Erion K, Florez JC et al (2020) Precision medicine in diabetes: a consensus report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 43(7):1617–1635. <https://doi.org/10.2337/dci20-0022>
- Zhou K, Yee SW, Seiser EL et al (2016) Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. *Nat Genet* 48(9):1055–1059. <https://doi.org/10.1038/ng.3632>
- Zhou K, Bellenguez C, Spencer CC et al (2011) Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. *Nat Genet* 43(2):117–120. <https://doi.org/10.1038/ng.735>
- Srinivasan S, Kaur V, Chamarthi B et al (2018) TCF7L2 Genetic variation augments incretin resistance and influences response to a sulfonylurea and metformin: the study to understand the genetics of the acute response to Metformin and Glipizide in Humans (SUGAR-MGH). *Diabetes Care* 41(3):554–561. <https://doi.org/10.2337/dc17-1386>
- Zhou K, Donnelly L, Burch L et al (2010) Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study. *Clin Pharmacol Ther* 87(1):52–56. <https://doi.org/10.1038/clpt.2009.176>
- Dujic T, Zhou K, Donnelly LA, Leese G, Palmer CNA, Pearson ER (2018) Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylurea-induced hypoglycaemia: A GoDARTS Study. *Diabetes Obes Metab* 20(1):211–214. <https://doi.org/10.1111/dom.13046>
- Chen L, Li JH, Kaur V et al (2020) The presence of two reduced function variants in CYP2C9 influences the acute response to glipizide. *Diabet Med* 37(12):2124–2130. <https://doi.org/10.1111/dme.14176>
- Dawed AY, Yee SW, Zhou K et al (2021) Genome-wide meta-analysis identifies genetic variants associated with glycemic response to sulfonylureas. *Diabetes Care* 44(12):2673–2682. <https://doi.org/10.2337/dc21-1152>
- Xue A, Wu Y, Zhu Z et al (2018) Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes. *Nat Commun* 9(1):2941. <https://doi.org/10.1038/s41467-018-04951-w>
- Florez JC, Jablonski KA, Bayley N et al (2006) TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. *N Engl J Med* 355(3):241–250. <https://doi.org/10.1056/NEJMoa062418>
- Lyssenko V, Lupi R, Marchetti P et al (2007) Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. *J Clin Invest* 117(8):2155–2163. <https://doi.org/10.1172/JCI30706>
- Villareal DT, Robertson H, Bell GI et al (2010) TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. *Diabetes* 59(2):479–485. <https://doi.org/10.2337/db09-1169>
- Walford GA, Colomo N, Todd JN et al (2015) The study to understand the genetics of the acute response to metformin and glipizide in humans (SUGAR-MGH): design of a pharmacogenetic resource for type 2 diabetes. *PLoS One* 10(3):e0121553. <https://doi.org/10.1371/journal.pone.0121553>
- Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ (2015) Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* 4:7. <https://doi.org/10.1186/s13742-015-0047-8>
- Delaneau O, Zagury J-F, Marchini J (2013) Improved whole-chromosome phasing for disease and population genetic studies. *Nat Methods* 10(1):5–6. <https://doi.org/10.1038/nmeth.2307>
- Taliun D, Harris DN, Kessler MD et al (2021) Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. *Nature* 590(7845):290–299. <https://doi.org/10.1038/s41586-021-03205-y>
- R Core Team (2017) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria
- Pruim RJ, Welch RP, Sanna S et al (2010) LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics (Oxford, England)* 26(18):2336–2337. <https://doi.org/10.1093/bioinformatics/btq419>

20. Vujkovic M, Keaton JM, Lynch JA et al (2020) Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. *Nat Genet* 52(7):680–691. <https://doi.org/10.1038/s41588-020-0637-y>
21. Mahajan A, Spracklen CN, Zhang W et al (2022) Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. *Nat Genet* 54(5):560–572. <https://doi.org/10.1038/s41588-022-01058-3>
22. Chen J, Spracklen CN, Marenne G et al (2021) The trans-ancestral genomic architecture of glycemic traits. *Nat Genet* 53(6):840–860. <https://doi.org/10.1038/s41588-021-00852-9>
23. Machiela MJ, Chanock SJ (2015) LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. *Bioinformatics* (Oxford, England) 31(21):3555–3557. <https://doi.org/10.1093/bioinformatics/btv402>
24. Giambartolomei C, Zhenli Liu J, Zhang W et al (2018) A Bayesian framework for multiple trait colocalization from summary association statistics. *Bioinformatics* (Oxford, England) 34(15):2538–2545. <https://doi.org/10.1093/bioinformatics/bty147>
25. Ge T, Chen C-Y, Ni Y, Feng Y-CA, Smoller JW (2019) Polygenic prediction via Bayesian regression and continuous shrinkage priors. *Nat Commun* 10(1):1776. <https://doi.org/10.1038/s41467-019-09718-5>
26. Udler MS, Kim J, von Grotthuss M et al (2018) Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft clustering analysis. *PLoS Med* 15(9):e1002654. <https://doi.org/10.1371/journal.pmed.1002654>
27. The Diabetes Prevention Program Research Group (2000) The Diabetes Prevention Program: baseline characteristics of the randomized cohort. *Diabetes Care* 23(11):1619–1629. <https://doi.org/10.2337/diacare.23.11.1619>
28. The Diabetes Prevention Program (1999) Design and methods for a clinical trial in the prevention of type 2 diabetes. *Diabetes Care* 22(4):623–634. <https://doi.org/10.2337/diacare.22.4.623>
29. Li JH, Perry JA, Jablonski KA et al (2022) Identification of genetic variation influencing metformin response in a multi-ancestry genome-wide association study in the Diabetes Prevention Program (DPP). *Diabetes*. <https://doi.org/10.2337/db22-0702>
30. Sung K-C, Reaven GM, Kim SH (2009) Utility of homeostasis model assessment of β -cell function in predicting diabetes in 12,924 healthy Koreans. *Diabetes Care* 33(1):200–202. <https://doi.org/10.2337/dc09-1070>
31. Song Y, Manson JE, Tinker L et al (2007) Insulin sensitivity and insulin secretion determined by homeostasis model assessment and risk of diabetes in a multiethnic cohort of women: the Women's Health Initiative Observational Study. *Diabetes Care* 30(7):1747–1752. <https://doi.org/10.2337/dc07-0358>
32. Li JH, Szczerbinski L, Dawed AY et al (2021) A polygenic score for type 2 diabetes risk is associated with both the acute and sustained response to sulfonylureas. *Diabetes* 70(1):293–300. <https://doi.org/10.2337/db20-0530>
33. Ohara-Imaizumi M, Aoyagi K, Ohtsuka T (2019) Role of the active zone protein, ELKS, in insulin secretion from pancreatic β -cells. *Mol Metab* 27(Suppl):S81–S91. <https://doi.org/10.1016/j.molmet.2019.06.017>
34. Omar-Hmeadi M, Idevall-Hagren O (2021) Insulin granule biogenesis and exocytosis. *Cell Mol Life Sci* 78(5):1957–1970. <https://doi.org/10.1007/s00018-020-03688-4>
35. Wrann CD, Eguchi J, Bozec A et al (2012) FOSL2 promotes leptin gene expression in human and mouse adipocytes. *J Clin Invest* 122(3):1010–1021. <https://doi.org/10.1172/jci58431>
36. Accelerating Medicines Partnership. T2D Knowledge Portal. Available from <https://t2d.hugeamp.org/region.html?chr=2&end=28690184&phenotype=TG&start=28565315>. Accessed 21 Sep 2022
37. Thomsen SK, Ceroni A, van de Bunt M et al (2016) Systematic functional characterization of candidate causal genes for type 2 diabetes risk variants. *Diabetes* 65(12):3805–3811. <https://doi.org/10.2337/db16-0361>
38. Ruetten H, Gebauer M, Raymond RH et al (2018) Mixed meal and intravenous L-arginine tests both stimulate incretin release across glucose tolerance in man: lack of correlation with β cell function. *Metab Syndr Relat Disord* 16(8):406–415. <https://doi.org/10.1089/met.2018.0022>
39. Dennis JM, Shields BM, Henley WE, Jones AG, Hattersley AT (2019) Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. *Lancet Diabetes Endocrinol* 7(6):442–451. [https://doi.org/10.1016/s2213-8587\(19\)30087-7](https://doi.org/10.1016/s2213-8587(19)30087-7)
40. The GTEx Consortium (2020) The GTEx Consortium atlas of genetic regulatory effects across human tissues. *Science* (New York, NY) 369(6509):1318–1330. <https://doi.org/10.1126/science.aaz1776>
41. Shu Y, Brown C, Castro RA et al (2008) Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. *Clin Pharmacol Ther* 83(2):273–280. <https://doi.org/10.1038/sj.clpt.6100275>
42. Zhou K, Donnelly LA, Kimber CH et al (2009) Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. *Diabetes* 58(6):1434–1439. <https://doi.org/10.2337/db08-0896>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Authors and Affiliations

Josephine H. Li^{1,2,3,4}  · Laura N. Brenner^{1,3,4,5} · Varinderpal Kaur^{1,2,3} · Katherine Figueroa^{1,3} · Philip Schroeder^{1,2,3}  ·
Alicia Huerta-Chagoya^{1,2,3}  · MAGIC Investigators · Diabetes Prevention Program (DPP) Research Group ·
Miriam S. Udler^{1,2,3,4}  · Aaron Leong^{1,2,3,4,6}  · Josep M. Mercader^{1,2,3,4}  · Jose C. Florez^{1,2,3,4} 

✉ Jose C. Florez
jcflorez@mgh.harvard.edu

¹ Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA

² Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA

³ Programs in Metabolism and Medical & Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, USA

⁴ Harvard Medical School, Boston, MA, USA

⁵ Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA, USA

⁶ Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA

Electronic supplementary material

Members of the Meta-Analysis of Glucose and Insulin-related traits Consortium (MAGIC)

Ji Chen^{1,2}, Cassandra N. Spracklen^{3,4}, Gaëlle Marenne^{2,5}, Arushi Varshney⁶, Laura J Corbin^{7,8}, Jian'an Luan⁹, Sara M Willems⁹, Ying Wu³, Xiaoshuai Zhang^{9,10}, Momoko Horikoshi^{11,12,13}, Thibaud S Boutin¹⁴, Reedik Mägi¹⁵, Johannes Waage¹⁶, Ruifang Li-Gao¹⁷, Kei Hang Katie Chan^{18,19,20}, Jie Yao²¹, Mila D Anasanti²², Audrey Y Chu²³, Anniqve Claringbould²⁴, Jani Heikkinen²², Jaeyoung Hong²⁵, Jouke-Jan Hottenga^{26,27}, Shaofeng Huo²⁸, Marika A. Kaakinen^{29,22}, Tin Louie³⁰, Winfried März^{31,32,33}, Hortensia Moreno-Macias³⁴, Anne Ndungu¹², Sarah C. Nelson³⁰, Ilja M. Nolte³⁵, Kari E North³⁶, Chelsea K. Raulerson³, Debashree Ray³⁷, Rebecca Rohde³⁶, Denis Rybin²⁵, Claudia Schurmann^{38,39}, Xueling Sim^{40,41,42}, Loz Southam², Isobel D Stewart⁹, Carol A. Wang⁴³, Yujie Wang³⁶, Peitao Wu²⁵, Weihua Zhang^{44,45}, Tarunveer S. Ahluwalia^{16,46,47}, Emil VR Appel⁴⁸, Lawrence F. Bielak⁴⁹, Jennifer A. Brody⁵⁰, Noël P Burti⁵¹, Claudia P Cabrera^{52,53}, Brian E Cade^{54,55}, Jin Fang Chai⁴⁰, Xiaoran Chai^{56,57}, Li-Ching Chang⁵⁸, Chien-Hsiun Chen⁵⁸, Brian H Chen⁵⁹, Kumaraswamy Naidu Chitrala⁶⁰, Yen-Feng Chiu⁶¹, Hugoline G. de Haan¹⁷, Graciela E Delgado³³, Ayse Demirkan^{62,29}, Qing Duan^{3,63}, Jorgen Engmann⁶⁴, Segun A Fatumo^{65,66,67}, Javier Gayán⁶⁸, Franco Giulianini⁶⁹, Jung Ho Gong¹⁸, Stefan Gustafsson⁷⁰, Yang Hai⁷¹, Fernando P Hartwig^{72,7}, Jing He⁷³, Yoriko Heianza⁷⁴, Tao Huang⁷⁵, Alicia Huerta-Chagoya^{76,77}, Mi Yeong Hwang⁷⁸, Richard A. Jensen⁵⁰, Takahisa Kawaguchi⁷⁹, Katherine A Kentistou^{80,81}, Young Jin Kim⁷⁸, Marcus E Kleber³³, Ishminder K Kooner⁴⁵, Shuiqing Lai¹⁸, Leslie A Lange⁸², Carl D Langefeld⁸³, Marie Lauzon²¹, Man Li⁸⁴, Symen Ligthart⁶², Jun Liu^{62,85}, Marie Loh^{86,44}, Jirong Long⁸⁷, Valeriya Lyssenko^{88,89}, Massimo Mangino^{90,91}, Carola Marzi^{92,93}, May E Montasser⁹⁴, Abhishek Nag¹², Masahiro Nakatochi⁹⁵, Damia Noce⁹⁶, Raymond Noordam⁹⁷, Giorgio Pistis⁹⁸, Michael Preuss^{38,99}, Laura Raffield³, Laura J. Rasmussen-Torvik¹⁰⁰, Stephen S Rich^{101,102}, Neil R Robertson^{11,12}, Rico Rueedi^{103,104}, Kathleen Ryan⁹⁴, Serena Sanna^{98,24}, Richa Saxena^{105,106,107}, Katharina E Schraut^{80,81}, Bengt Sennblad¹⁰⁸, Kazuya Setoh⁷⁹, Albert V Smith^{109,110}, Lorraine Southam^{111,112}, Thomas Sparsø⁴⁸, Rona J Strawbridge^{113,114}, Fumihiko Takeuchi¹¹⁵, Jingyi Tan²¹, Stella Trompet^{97,116}, Erik van den Akker^{117,118,119}, Peter J van der Most³⁵, Niek Verweij^{120,121}, Mandy Vogel¹²², Heming Wang^{54,55}, Chaolong Wang^{123,124}, Nan Wang^{125,126}, Helen R Warren^{52,53}, Wanqing Wen⁸⁷, Tom Wilsgaard¹²⁷, Andrew Wong¹²⁸, Andrew R Wood¹, Tian Xie³⁵, Mohammad Hadi Zafarmand^{129,130}, Jing-Hua Zhao¹³¹, Wei Zhao⁴⁹, Najaf Amin^{62,85}, Zorayr Arzumanyan²¹, Arne Astrup¹³², Stephan JL Bakker¹³³, Damiano Baldassarre^{134,135}, Marian Beekman¹¹⁷, Richard N Bergman¹³⁶, Alain Bertoni¹³⁷, Matthias Blüher¹³⁸, Lori L. Bonnycastle¹³⁹, Stefan R Bornstein¹⁴⁰, Donald W Bowden¹⁴¹, Qiuyin Cai⁷³, Archie Campbell^{142,143}, Harry Campbell⁸⁰, Yi Cheng Chang^{144,145,146}, Eco J.C. de Geus^{26,27}, Abbas Dehghan⁶², Shufa Du¹⁴⁷, Gudny Eiriksdottir¹¹⁰, Alike Eleni Farmaki^{148,149}, Mattias Frånberg¹⁵⁰, Christian Fuchsberger⁹⁶, Yutang Gao¹⁵¹, Anette P Gjesing⁴⁸, Anuj Goel^{152,12}, Sohee Han⁷⁸, Catharina A Hartman¹⁵³, Christian Herder^{154,155,156}, Andrew A. Hicks⁹⁶, Chang-Hsun Hsieh^{157,158}, Willa A. Hsueh¹⁵⁹, Sahoko Ichihara¹⁶⁰, Michiya Igase¹⁶¹, M. Arfan Ikram⁶², W. Craig Johnson³⁰, Marit E Jørgensen^{46,162}, Peter K Joshi⁸⁰, Rita R Kalyani¹⁶³, Fouad R. Kandeel¹⁶⁴, Tomohiro Katsuya^{165,166}, Chiea Chuen Khor¹²⁴, Wieland Kiess¹²², Ivana Kolcic¹⁶⁷, Teemu Kuulasmaa¹⁶⁸, Johanna Kuusisto¹⁶⁹, Kristi Läll¹⁵, Kelvin Lam²¹, Deborah A Lawlor^{170,8}, Nanette R. Lee^{171,172}, Rozenn N. Lemaitre⁵⁰, Honglan Li¹⁷³, Shih-Yi Lin^{174,175,176}, Jaana Lindström¹⁷⁷, Allan Linneberg^{178,179}, Jianjun Liu^{124,180}, Carlos Lorenzo¹⁸¹, Tatsuaki Matsubara¹⁸², Fumihiko Matsuda⁷⁹, Geltrude Mingrone¹⁸³, Simon Mooijaart⁹⁷, Sanghoon Moon⁷⁸, Toru Nabika¹⁸⁴, Girish N. Nadkarni³⁸, Jerry L. Nadler¹⁸⁵, Mari Nelis¹⁵, Matt J Neville^{11,186}, Jill M Norris¹⁸⁷, Yasumasa Ohayagi¹⁸⁸, Annette Peters^{189,93,190}, Patricia A. Peyser⁴⁹, Ozren Polasek^{167,191}, Qibin Qi¹⁹², Dennis Raven¹⁵³, Dermot F Reilly¹⁹³, Alex Reiner¹⁹⁴, Fernando Rivideneira¹⁹⁵, Kathryn Roll²¹, Igor Rudan¹⁹⁶, Charumathi Sabanayagam^{56,197}, Kevin Sandow²¹, Naveed Sattar¹⁹⁸, Annette Schürmann^{199,200}, Jinxiu Shi²⁰¹, Heather M Stringham^{42,41}, Kent D. Taylor²¹, Tanya M. Teslovich²⁰², Betina Thuesen¹⁷⁸, Paul RHJ Timmers^{80,203}, Elena Tremoli¹³⁵, Michael Y Tsai²⁰⁴, Andre Uitterlinden¹⁹⁵, Rob M van Dam^{40,180,205}, Diana van Heemst⁹⁷, Astrid van Hylckama Vlieg¹⁷, Jana V Van Vliet-Ostaptchouk³⁵, Jagadish Vangipurapu²⁰⁶, Henrik Vestergaard^{48,207}, Tao Wang¹⁹², Ko Willems van Dijk^{208,209,210}, Tatijana Zemunik²¹¹, Goncalo R Abecasis⁴², Linda S. Adair^{147,212}, Carlos Alberto Aguilar-Salinas^{213,214,215}, Marta E Alarcón-Riquelme^{216,217}, Ping An²¹⁸, Larissa Aviles-Santa²¹⁹, Diane M Becker²²⁰, Lawrence J Beilin²²¹, Sven Bergmann^{103,104,222}, Hans Bisgaard¹⁶, Corri Black²²³, Michael Boehnke^{42,41}, Eric Boerwinkle^{224,225}, Bernhard O Böhm^{226,227}, Klaus Bønnelykke¹⁶, D I. Boomsma^{26,27}, Erwin P. Bottinger^{38,228,229}, Thomas A Buchanan^{230,231,126}, Mickaël Canouil^{232,233}, Mark J Caulfield^{52,53}, John C. Chambers^{86,44,45,234,235}, Daniel I. Chasman^{69,236}, Yii-Der Ida Chen²¹, Ching-Yu Cheng^{56,197}, Francis S. Collins¹³⁹, Adolfo Correa²³⁷, Francesco Cucca⁹⁸, H. Janaka de Silva²³⁸,

George Dedoussis²³⁹, Sölve Elmståhl²⁴⁰, Michele K. Evans²⁴¹, Ele Ferrannini²⁴², Luigi Ferrucci²⁴³, Jose C Florez^{244,245,107}, Paul W Franks^{89,246}, Timothy M Frayling¹, Philippe Froguel^{232,233,247}, Bruna Gigante²⁴⁸, Mark O. Goodarzi²⁴⁹, Penny Gordon-Larsen^{147,212}, Harald Grallert^{92,93}, Niels Grarup⁴⁸, Sameline Grimsgaard¹²⁷, Leif Groop^{250,251}, Vilmundur Gudnason^{110,252}, Xiuqing Guo²¹, Anders Hamsten¹¹⁴, Torben Hansen⁴⁸, Caroline Hayward²⁰³, Susan R. Heckbert²⁵³, Bernardo L Horta⁷², Wei Huang²⁰¹, Erik Ingelsson²⁵⁴, Pankow S James²⁵⁵, Marjo-Ritta Jarvelin^{256,257,258,259}, Jost B Jonas^{260,261,262}, J. Wouter Jukema^{116,263}, Pontiano Kaleebu²⁶⁴, Robert Kaplan^{192,194}, Sharon L.R. Kardia⁴⁹, Norihiro Kato¹¹⁵, Sirkka M. Keinanen-Kiukaanniemi^{265,266}, Bong-Jo Kim⁷⁸, Mika Kivimaki²⁶⁷, Heikki A. Koistinen^{268,269,270}, Jaspal S. Kooner^{45,234,235,271}, Antje Körner¹²², Peter Kovacs^{138,272}, Diana Kuh¹²⁸, Meena Kumari²⁷³, Zoltan Kutalik^{274,104}, Markku Laakso¹⁶⁹, Timo A. Lakka^{275,276,277}, Lenore J Launer⁶⁰, Karin Leander²⁷⁸, Huaixing Li²⁸, Xu Lin²⁸, Lars Lind²⁷⁹, Cecilia Lindgren^{12,280,281}, Simin Liu¹⁸, Ruth J.F. Loos^{38,99}, Patrik KE Magnusson²⁸², Anubha Mahajan¹², Andres Metspalu¹⁵, Dennis O Mook-Kanamori^{17,283}, Trevor A Mori²²¹, Patricia B Munroe^{52,53}, Inger Njølstad¹²⁷, Jeffrey R O'Connell⁹⁴, Albertine J Oldehinkel¹⁵³, Ken K Ong⁹, Sandosh Padmanabhan²⁸⁴, Colin N.A. Palmer²⁸⁵, Nicholette D Palmer¹⁴¹, Oluf Pedersen⁴⁸, Craig E Pennell⁴³, David J Porteous^{142,286}, Peter P. Pramstaller⁹⁶, Michael A. Province²¹⁸, Bruce M. Psaty^{50,253,287}, Lu Qi²⁸⁸, Leslie J. Raffel²⁸⁹, Rainer Rauramaa²⁷⁷, Susan Redline^{54,55}, Paul M Ridker^{69,290}, Frits R. Rosendaal¹⁷, Timo E. Saaristo^{291,292}, Manjinder Sandhu²⁹³, Jouko Saramies²⁹⁴, Neil Schneiderman²⁹⁵, Peter Schwarz^{140,296,200}, Laura J. Scott^{42,41}, Elizabeth Selvin³⁷, Peter Sever²⁷¹, Xiao-ou Shu⁸⁷, P Eline Slagboom¹¹⁷, Kerrin S Small⁹⁰, Blair H Smith²⁹⁷, Harold Snieder³⁵, Tamar Sofer^{298,245}, Thorkild I.A. Sørensen^{48,299,7,8}, Tim D Spector⁹⁰, Alice Stanton³⁰⁰, Claire J Steves^{90,301}, Michael Stumvoll¹³⁸, Liang Sun²⁸, Yasuharu Tabara⁷⁹, E Shyong Tai^{180,40,302}, Nicholas J Timpson^{7,8}, Anke Tönjes¹³⁸, Jaakko Tuomilehto^{303,304,305}, Teresa Tusie^{77,306}, Matti Uusitupa³⁰⁷, Pim van der Harst^{120,24}, Cornelia van Duijn^{85,62}, Veronique Vitart²⁰³, Peter Vollenweider³⁰⁸, Tanja GM Vrijkotte¹²⁹, Lynne E Wagenknecht³⁰⁹, Mark Walker³¹⁰, Ya X Wang²⁶¹, Nick J Wareham⁹, Richard M Watanabe^{125,231,126}, Hugh Watkins^{152,12}, Wen B Wei³¹¹, Ananda R Wickremasinghe³¹², Gonneke Willemsen^{26,27}, James F Wilson^{80,203}, Tien-Yin Wong^{56,197}, Jer-Yuarn Wu⁵⁸, Anny H Xiang³¹³, Lisa R Yanek²²⁰, Loic Yengo³¹⁴, Mitsuhiro Yokota³¹⁵, Eleftheria Zeggini^{111,316,317}, Wei Zheng⁸⁷, Alan B Zonderman⁶⁰, Jerome I Rotter²¹, Anna L Gloyn^{11,12,186,318}, Mark I. McCarthy^{11,319,186,12}, Josée Dupuis²⁵, James B Meigs^{320,245,107}, Robert A Scott⁹, Inga Prokopenko^{29,22}, Aaron Leong^{321,322,236}, Ching-Ti Liu²⁵, Stephen CJ Parker^{6,323#}, Karen L. Mohlke³, Claudia Langenberg⁹, Eleanor Wheeler^{2,9}, Andrew P. Morris^{324,325,326,12}, Inês Barroso^{1,2,9,327} and the Meta-Analysis of Glucose and Insulin-related Traits Consortium (MAGIC)*

¹Exeter Centre of Excellence for Diabetes Research (ExCEED), Genetics of Complex Traits, University of Exeter Medical School, University of Exeter, Exeter, UK, ²Department of Human Genetics, Wellcome Sanger Institute, Hinxton, Cambridge, UK, ³Department of Genetics, University of North Carolina, Chapel Hill, NC, USA, ⁴Department of Biostatistics and Epidemiology, University of Massachusetts, Amherst, MA, USA, ⁵Inserm, Univ Brest, EFS, UMR 1078, GGB, Brest, France, ⁶Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA, ⁷MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK, ⁸Department of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK, ⁹MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, UK, ¹⁰Department of Biostatistics, School of Public Health, Shandong University, Jinan, Shandong, China, ¹¹Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, UK, ¹²Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK, ¹³Laboratory for Genomics of Diabetes and Metabolism, RIKEN Centre for Integrative Medical Sciences, Yokohama, Japan, ¹⁴Medical Research Council Human Genetics Unit, Institute for Genetics and Molecular Medicine, Edinburgh, UK, ¹⁵Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia, ¹⁶COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark, ¹⁷Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands, ¹⁸Department of Epidemiology, Brown University School of Public Health, Brown University, Providence, RI, USA, ¹⁹Department of Biomedical Sciences, City University of Hong Kong, Hong Kong SAR, China, ²⁰Department of Electrical Engineering, City University of Hong Kong, Hong Kong SAR, China, ²¹The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA, ²²Department of Metabolism, Digestion, and Reproduction, Imperial College London, London, UK, ²³Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA,

USA, ²⁴Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, ²⁵Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA, ²⁶Department of Biological Psychology, Faculty of Behaviour and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands, ²⁷Amsterdam Public Health Research Institute, Amsterdam Universities Medical Center, Amsterdam, The Netherlands, ²⁸CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China, ²⁹Section of Statistical Multi-omics, Department of Clinical and Experimental Research, University of Surrey, Guildford, Surrey, UK, ³⁰Department of Biostatistics, University of Washington, Seattle, WA, USA, ³¹SYNLAB Academy, SYNLAB Holding Deutschland GmbH, Mannheim, Germany, ³²Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University Graz, Graz, Austria, ³³Vth Department of Medicine (Nephrology, Hypertensiology, Rheumatology, Endocrinology, Diabetology), Medical Faculty Mannheim, Heidelberg University, Mannheim, Baden-Württemberg, Germany, ³⁴Department of Economics, Metropolitan Autonomous University, Mexico City, Mexico, ³⁵Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, ³⁶CVD Genetic Epidemiology Computational Laboratory, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA, ³⁷Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, ³⁸The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA, ³⁹HPI Digital Health Center, Digital Health and Personalized Medicine, Hasso Plattner Institute, Potsdam, Germany, ⁴⁰Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore, ⁴¹Center for Statistical Genetics, University of Michigan, Ann Arbor, MI, USA, ⁴²Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor, MI, USA, ⁴³School of Medicine and Public Health, College of Health, Medicine and Wellbeing, The University of Newcastle, Newcastle, NSW, Australia, ⁴⁴Department of Epidemiology and Biostatistics, Imperial College London, London, UK, ⁴⁵Department of Cardiology, Ealing Hospital, London North West Healthcare NHS Trust, Middlesex, UK, ⁴⁶Steno Diabetes Center Copenhagen, Gentofte, Denmark, ⁴⁷The Bioinformatics Centre, Department of Biology, University of Copenhagen, Copenhagen, Denmark, ⁴⁸Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, ⁴⁹Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA, ⁵⁰Department of Medicine, Cardiovascular Health Research Unit, University of Washington, Seattle, WA, USA, ⁵¹Metabolism Program, Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA, ⁵²Department of Clinical Pharmacology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK, ⁵³NIHR Barts Cardiovascular Biomedical Research Centre, Queen Mary University of London, London, UK, ⁵⁴Department of Medicine, Sleep and Circadian Disorders, Brigham and Women's Hospital, Boston, MA, USA, ⁵⁵Department of Medicine, Sleep Medicine, Harvard Medical School, Boston, MA, USA, ⁵⁶Ocular Epidemiology, Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore, ⁵⁷Department of Ophthalmology, National University of Singapore and National University Health System, Singapore, Singapore, ⁵⁸Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, Taiwan, ⁵⁹Department of Epidemiology, The Herbert Wertheim School of Public Health and Human Longevity Science, UC San Diego, La Jolla, CA, USA, ⁶⁰Laboratory of Epidemiology and Population Sciences, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA, ⁶¹Institute of Population Health Sciences, National Health Research Institutes, Miaoli, Taiwan, ⁶²Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands, ⁶³Department of Statistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, ⁶⁴Institute of Cardiovascular Science, UCL, London, UK, ⁶⁵Uganda Medical Informatics Centre (UMIC), MRC/UVRI and London School of Hygiene & Tropical Medicine (Uganda Research Unit), Entebbe, Uganda, ⁶⁶London School of Hygiene & Tropical Medicine, London, UK, ⁶⁷H3Africa Bioinformatics Network (H3ABioNet) Node, Centre for Genomics Research and Innovation, NABDA/FMST, Abuja, Nigeria, ⁶⁸Bioinfosol, Sevilla, Spain, ⁶⁹Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA, USA, ⁷⁰Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden, ⁷¹Department of Statistics, The University of Auckland, Science Center, Auckland, New Zealand, ⁷²Postgraduate Program in Epidemiology, Federal University of Pelotas, Pelotas, RS, Brazil, ⁷³Department of Medicine, Epidemiology, Vanderbilt University Medical Center, Nashville, TN, USA, ⁷⁴Department of Epidemiology, Tulane University Obesity Research Center, Tulane University, New Orleans, USA, ⁷⁵Department of Epidemiology and Biostatistics,

School of Public Health, Peking University, Beijing, China, ⁷⁶Molecular Biology and Genomic Medicine Unit, National Council for Science and Technology, Mexico City, Mexico, ⁷⁷Molecular Biology and Genomic Medicine Unit, National Institute of Medical Sciences and Nutrition, Mexico City, Mexico, ⁷⁸Division of Genome Science, Department of Precision Medicine, National Institute of Health, Cheongju-si, Chungcheongbuk-do, South Korea, ⁷⁹Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁸⁰Centre for Global Health Research, Usher Institute, University of Edinburgh, Edinburgh, Scotland, ⁸¹Centre for Cardiovascular Sciences, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, Scotland, ⁸²Department of Medicine, Division of Biomedical Informatics and Personalized Medicine, University of Colorado Anschutz Medical Campus, Denver, CO, USA, ⁸³Department of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, NC, USA, ⁸⁴Department of Medicine, Division of Nephrology and Hypertension, University of Utah, Salt Lake City, UT, USA, ⁸⁵Nuffield Department of Population Health, University of Oxford, Oxford, UK, ⁸⁶Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore, ⁸⁷Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt University Medical Center, Nashville, TN, USA, ⁸⁸Department of Clinical Science, Center for Diabetes Research, University of Bergen, Bergen, Norway, ⁸⁹Department of Clinical Sciences, Lund University Diabetes Centre, Lund University, Malmo, Sweden, ⁹⁰Department of Twin Research and Genetic Epidemiology, School of Life Course Sciences, King's College London, London, UK, ⁹¹NIHR Biomedical Research Centre, Guy's and St Thomas' Foundation Trust, London, UK, ⁹²Institute of Epidemiology, Research Unit of Molecular Epidemiology, Helmholtz Zentrum München Research Center for Environmental Health, Neuherberg, Bavaria, Germany, ⁹³German Center for Diabetes Research (DZD), Neuherberg, Bavaria, Germany, ⁹⁴Department of Medicine, Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine, Baltimore, MD, USA, ⁹⁵Public Health Informatics Unit, Department of Integrated Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁹⁶Institute for Biomedicine, Eurac Research, Bolzano, BZ, Italy, ⁹⁷Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands, ⁹⁸Istituto di Ricerca Genetica e Biomedica (IRGB), Consiglio Nazionale delle Ricerche (CNR), Monserrato, Italy, ⁹⁹The Mindich Child Health and Development Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA, ¹⁰⁰Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA, ¹⁰¹Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA, ¹⁰²Department of Public Health Sciences, University of Virginia, Charlottesville, VA, USA, ¹⁰³Department of Computational Biology, University of Lausanne, Lausanne, Switzerland, ¹⁰⁴Swiss Institute of Bioinformatics, Lausanne, Switzerland, ¹⁰⁵Center for Genomic Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, ¹⁰⁶Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA, USA, ¹⁰⁷Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA, ¹⁰⁸Department of Cell and Molecular Biology, National Bioinformatics Infrastructure Sweden, Science for Life Laboratory, Uppsala University, Uppsala, Sweden, ¹⁰⁹Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA, ¹¹⁰Icelandic Heart Association, Kopavogur, Iceland, ¹¹¹Institute of Translational Genomics, Helmholtz Zentrum München – German Research Center for Environmental Health, Neuherberg, Germany, ¹¹²Wellcome Sanger Institute, Hinxton, Cambridge, UK, ¹¹³Institute of Health and Wellbeing, University of Glasgow, Glasgow, Glasgow, UK, ¹¹⁴Department of Medicine Solna, Cardiovascular medicine, Karolinska Institutet, Stockholm, Sweden, ¹¹⁵National Center for Global Health and Medicine, Tokyo, Japan, ¹¹⁶Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands, ¹¹⁷Department of Biomedical Data Sciences, Molecular Epidemiology, Leiden University Medical Center, Leiden, The Netherlands, ¹¹⁸Department of Pattern Recognition & Bioinformatics, Delft University of Technology, Delft, The Netherlands, ¹¹⁹Department of Biomedical Data Sciences, Leiden Computational Biology Center, Leiden University Medical Center, Leiden, The Netherlands, ¹²⁰Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, ¹²¹Genomics plc, Oxford, UK, ¹²²Center of Pediatric Research, University Children's Hospital Leipzig, University of Leipzig Medical Center, Leipzig, Germany, ¹²³Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, ¹²⁴Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore, ¹²⁵Department of Preventive Medicine, Keck School of Medicine of USC, Los Angeles, CA, USA, ¹²⁶USC Diabetes and Obesity Research Institute, Keck School of Medicine of USC, Los Angeles, CA, USA, ¹²⁷Department of Community Medicine, Faculty of Health Sciences, UIT the Arctic University of Norway, Tromsø, Norway, ¹²⁸MRC Unit for

Lifelong Health & Ageing at UCL, London, UK, ¹²⁹Department of Public Health, Amsterdam Public Health Research Institute, Amsterdam Universities Medical Center, Amsterdam, The Netherlands, ¹³⁰Department of Clinical Epidemiology, Biostatistics, and Bioinformatics, Amsterdam Public Health Research Institute, Amsterdam Universities Medical Center, Amsterdam, The Netherlands, ¹³¹Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK, ¹³²Department of Nutrition, Exercise, and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark, ¹³³Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, ¹³⁴Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy, ¹³⁵Centro Cardiologico Monzino, IRCCS, Milan, Italy, ¹³⁶Diabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA, ¹³⁷Department of Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA, ¹³⁸Medical Department III – Endocrinology, Nephrology, Rheumatology, University of Leipzig Medical Center, Leipzig, Germany, ¹³⁹Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA, ¹⁴⁰Department for Prevention and Care of Diabetes, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, ¹⁴¹Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC, USA, ¹⁴²Centre for Genomic and Experimental Medicine, Institute of Genetics & Molecular Medicine, University of Edinburgh, Western General Hospital, Edinburgh, UK, ¹⁴³Usher Institute, University of Edinburgh, Edinburgh, UK, ¹⁴⁴Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, ¹⁴⁵Graduate Institute of Medical Genomics and Proteomics, National Taiwan University, Taipei, Taiwan, ¹⁴⁶Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, ¹⁴⁷Department of Nutrition, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA, ¹⁴⁸Department of Population Science and Experimental Medicine, Institute of Cardiovascular Science, University College London, London, UK, ¹⁴⁹Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University of Athens, Athens, Greece, ¹⁵⁰Department of Medicine Solna, Cardiovascular medicine, Stockholm, Sweden, ¹⁵¹Department of Epidemiology, Shanghai Cancer Institute, Shanghai, China, ¹⁵²Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK, ¹⁵³Department of Psychiatry, Interdisciplinary Center Psychopathology and Emotion Regulation, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, ¹⁵⁴Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany, ¹⁵⁵Division of Endocrinology and Diabetology, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany, ¹⁵⁶German Center for Diabetes Research (DZD), Düsseldorf, Germany, ¹⁵⁷Internal Medicine, Endocrine & Metabolism, Tri-Service General Hospital, Taipei, Taiwan, ¹⁵⁸School of Medicine, National Defense Medical Center, Taipei, Taiwan, ¹⁵⁹Internal Medicine, Endocrinology, Diabetes & Metabolism, Diabetes and Metabolism Research Center, The Ohio State University Wexner Medical Center, Columbus, OH, USA, ¹⁶⁰Department of Environmental and Preventive Medicine, Jichi Medical University School of Medicine, Shimotsuke, Japan, ¹⁶¹Department of Anti-aging Medicine, Ehime University Graduate School of Medicine, Toon, Japan, ¹⁶²National Institute of Public Health, University of Southern Denmark, Odense, Denmark, ¹⁶³Department of Medicine, Endocrinology, Diabetes & Metabolism, Johns Hopkins University School of Medicine, Baltimore, MD, USA, ¹⁶⁴Clinical Diabetes, Endocrinology & Metabolism, Translational Research & Cellular Therapeutics, Beckman Research Institute of the City of Hope, Duarte, CA, USA, ¹⁶⁵Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine, Suita, Japan, ¹⁶⁶Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine, Suita, Japan, ¹⁶⁷Department of Public Health, University of Split School of Medicine, Split, Croatia, ¹⁶⁸Institute of Biomedicine, Bioinformatics Center, University of Eastern Finland, Kuopio, Finland, ¹⁶⁹Department of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland, ¹⁷⁰MRC Integrative Epidemiology Unit, University of Bristol, Bristol, Bristol, UK, ¹⁷¹USC-Office of Population Studies Foundation, University of San Carlos, Cebu City, Philippines, ¹⁷²Department of Anthropology, Sociology and History, University of San Carlos, Cebu City, Philippines, ¹⁷³State Key Laboratory of Oncogene and Related Genes & Department of Epidemiology, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, ¹⁷⁴Internal Medicine, Endocrine & Metabolism, Taichung Veterans General Hospital, Taichung, Taiwan, ¹⁷⁵Center for Geriatrics and Gerontology, Taichung Veterans General Hospital, Taichung, Taiwan, ¹⁷⁶National Defense Medical Center, National Yang-Ming University, Taipei, Taiwan, ¹⁷⁷Diabetes Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland, ¹⁷⁸Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg

Hospital, Copenhagen, Denmark, ¹⁷⁹Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, ¹⁸⁰Yong Loo Lin School of Medicine, National University of Singapore and National University Health System, Singapore, Singapore, ¹⁸¹Department of Medicine, University of Texas Health Sciences Center, San Antonio, TX, USA, ¹⁸²Department of Internal Medicine, Aichi Gakuin University School of Dentistry, Nagoya, Japan, ¹⁸³Department of Diabetes, Diabetes, & Nutritional Sciences, James Black Centre, King's College London, London, UK, ¹⁸⁴Department of Functional Pathology, Shimane University School of Medicine, Izumo, Japan, ¹⁸⁵Department of Medicine and Pharmacology, New York Medical College School of Medicine, Valhalla, NY, USA, ¹⁸⁶Oxford NIHR Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, ¹⁸⁷Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, ¹⁸⁸Department of Geriatric Medicine and Neurology, Ehime University Graduate School of Medicine, Toon, Japan, ¹⁸⁹Institute of Epidemiology, Helmholtz Zentrum München Research Center for Environmental Health, Neuherberg, Bavaria, Germany, ¹⁹⁰Institute for Medical Information Processing, Biometry, and Epidemiology, Ludwig-Maximilians University Munich, Munich, Bavaria, Germany, ¹⁹¹Gen-info Ltd, Zagreb, Croatia, ¹⁹²Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA, ¹⁹³Genetics and Pharmacogenomics, Merck Sharp & Dohme Corp., Kenilworth, NJ, USA, ¹⁹⁴Department of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA, ¹⁹⁵Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands, ¹⁹⁶Centre for Global Health, The Usher Institute, University of Edinburgh, Edinburgh, UK, ¹⁹⁷Ophthalmology & Visual Sciences Academic Clinical Program (Eye ACP), Duke-NUS Medical School, Singapore, Singapore, ¹⁹⁸BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK, ¹⁹⁹Department of Experimental Diabetology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany, ²⁰⁰German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany, ²⁰¹Department of Genetics, Shanghai-MOST Key Laboratory of Health and Disease Genomics, Chinese National Human Genome Center at Shanghai (CHGC) and Shanghai Academy of Science & Technology (SAST), Shanghai, China, ²⁰²Sarepta Therapeutics, Cambridge, Massachusetts, USA, ²⁰³Medical Research Council Human Genetics Unit, Institute for Genetics and Cancer, University of Edinburgh, Edinburgh, UK, ²⁰⁴Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA, ²⁰⁵Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA, ²⁰⁶Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, Finland, ²⁰⁷Department of Medicine, Bornholms Hospital, Rønne, Denmark, ²⁰⁸Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands, ²⁰⁹Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands, ²¹⁰Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands, ²¹¹Department of Human Biology, University of Split School of Medicine, Split, Croatia, ²¹²Carolina Population Center, University of North Carolina, Chapel Hill, NC, USA, ²¹³Department of Endocrinology and Metabolism, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ²¹⁴Unidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición and Tec Salud, Mexico City, Mexico, ²¹⁵Instituto Tecnológico y de Estudios Superiores de Monterrey Tec Salud, Mexico City, Mexico, ²¹⁶Department of Medical Genomics, Pfizer/University of Granada/Andalusian Government Center for Genomics and Oncological Research (GENYO), Granada, Spain, ²¹⁷Institute for Environmental Medicine, Chronic Inflammatory Diseases, Karolinska Institutet, Solna, Sweden, ²¹⁸Department of Genetics, Division of Statistical Genomics, Washington University School of Medicine, St. Louis, MO, USA, ²¹⁹Clinical and Health Services Research, National Institute on Minority Health and Health Disparities, Bethesda, MD, USA, ²²⁰Department of Medicine, General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA, ²²¹Medical School, Royal Perth Hospital Unit, University of Western Australia, Perth, WA, Australia, ²²²Department of Integrative Biomedical Sciences, University of Cape Town, Cape Town, South Africa, ²²³Aberdeen Centre for Health Data Science, 1:042 Polwarth Building., School of Medicine, Medical, Science and Nutrition, University of Aberdeen, Foresterhill, Aberdeen, UK, ²²⁴Human Genetics Center, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, USA, ²²⁵Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA, ²²⁶Division of Endocrinology and Diabetes, Graduate School of Molecular Endocrinology and Diabetes, University of Ulm, Ulm, Baden-Württemberg, Germany, ²²⁷LKC School of Medicine, Nanyang Technological University, Singapore and Imperial College London, UK, Singapore, Singapore, ²²⁸Hasso Plattner Institute for Digital Health at Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, NY, USA,

²²⁹Digital Health Center, Hasso Plattner Institut, University Potsdam, Potsdam, Germany, ²³⁰Department of Medicine, Keck School of Medicine of USC, Los Angeles, CA, USA, ²³¹Department of Physiology and Neuroscience, Keck School of Medicine of USC, Los Angeles, CA, USA, ²³²INSERM UMR 1283 / CNRS UMR 8199, European Institute for Diabetes (EGID), Université de Lille, Lille, France, ²³³INSERM UMR 1283 / CNRS UMR 8199, European Institute for Diabetes (EGID), Institut Pasteur de Lille, Lille, France, ²³⁴Imperial College Healthcare NHS Trust, Imperial College London, London, UK, ²³⁵MRC-PHE Centre for Environment and Health, Imperial College London, London, UK, ²³⁶Harvard Medical School, Boston, MA, USA, ²³⁷Department of Medicine, Jackson Heart Study, University of Mississippi Medical Center, Jackson, MS, USA, ²³⁸Department of Medicine, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka, ²³⁹Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University of Athens, Kallithea, Greece, ²⁴⁰Department of Clinical Sciences, Lund University, Malmö, Sweden, ²⁴¹Laboratory of Epidemiology and Population Sciences, National Institute on Aging Intramural Research Program, National Institutes of Health, Baltimore, MD, USA, ²⁴²CNR Institute of Clinical Physiology, Pisa, Italy, ²⁴³Intramural Research Program, National Institute of Aging, Baltimore, MD, USA, ²⁴⁴Diabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA, ²⁴⁵Department of Medicine, Harvard Medical School, Boston, MA, USA, ²⁴⁶Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden, ²⁴⁷Department of Genomics of Common Disease, Imperial College London, London, UK, ²⁴⁸Department of Medicine, Cardiovascular medicine, Karolinska Institutet, Stockholm, Sweden, ²⁴⁹Department of Medicine, Division of Endocrinology, Diabetes & Metabolism, Cedars-Sinai Medical Center, Los Angeles, CA, USA, ²⁵⁰Diabetes Centre, Lund University, Sweden, ²⁵¹Finnish Institute of Molecular Medicine, Helsinki University, Helsinki, Finland, ²⁵²Faculty of Medicine, School of health sciences, University of Iceland, Reykjavik, Iceland, ²⁵³Department of Epidemiology, Cardiovascular Health Research Unit, University of Washington, Seattle, WA, USA, ²⁵⁴Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford University, Stanford, CA, USA, ²⁵⁵Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, MN, USA, ²⁵⁶Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London, UK, ²⁵⁷Center for Life Course Health Research, Faculty of Medicine, University of Oulu, Oulu, Finland, ²⁵⁸Unit of Primary Health Care, Oulu University Hospital, OYS, Oulu, Finland, ²⁵⁹Department of Life Sciences, College of Health and Life Sciences, Brunel University London, London, UK, ²⁶⁰Department of Ophthalmology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany, ²⁶¹Beijing Institute of Ophthalmology, Beijing Ophthalmology and Visual Science Key Lab, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China, ²⁶²Institute of Molecular and Clinical Ophthalmology Basel IOB, Basel, Switzerland, ²⁶³Netherlands Heart Institute, Utrecht, The Netherlands, ²⁶⁴MRC/UVRI and LSHTM (Uganda Research Unit), Entebbe, Uganda, ²⁶⁵Faculty of Medicine, Institute of Health Sciences, University of Oulu, Oulu, Finland, ²⁶⁶Unit of General Practice, Oulu University Hospital, Oulu, Finland, ²⁶⁷Department of Epidemiology and Public Health, UCL, London, UK, ²⁶⁸Department of Public Health Solutions, Finnish Institute for Health and Welfare, Helsinki, Finland, ²⁶⁹Department of Medicine, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland, ²⁷⁰Minerva Foundation Institute for Medical Research, Helsinki, Finland, ²⁷¹National Heart and Lung Institute, Imperial College London, London, UK, ²⁷²IFB Adiposity Diseases, University of Leipzig Medical Center, Leipzig, Germany, ²⁷³Institute for Social and Economic Research, University of Essex, Colchester, UK, ²⁷⁴University Institute of Primary Care and Public Health, Division of Biostatistics, University of Lausanne, Lausanne, Switzerland, ²⁷⁵Institute of Biomedicine, School of Medicine, University of Eastern Finland, Finland, ²⁷⁶Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Kuopio, Finland, ²⁷⁷Foundation for Research in Health Exercise and Nutrition, Kuopio Research Institute of Exercise Medicine, Kuopio, Finland, ²⁷⁸Institute of Environmental Medicine, Cardiovascular and Nutritional Epidemiology, Karolinska Institutet, Stockholm, Sweden, ²⁷⁹Department of Medical Sciences, Uppsala, Sweden, ²⁸⁰Big Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK, ²⁸¹Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, UK, ²⁸²Department of Medical Epidemiology and Biostatistics and the Swedish Twin Registry, Karolinska Institutet, Stockholm, Sweden, ²⁸³Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands, ²⁸⁴Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK, ²⁸⁵Division of Population Health and Genomics, School of Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK, ²⁸⁶Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK, ²⁸⁷Department of Health Services,

Cardiovascular Health Research Unit, University of Washington, Seattle, WA, USA, ²⁸⁸Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA, ²⁸⁹Department of Pediatrics, Genetic and Genomic medicine, University of California, Irvine, Irvine, CA, USA, ²⁹⁰Harvard Medical School, Boston, MA, USA, ²⁹¹Tampere, Finnish Diabetes Association, Tampere, Finland, ²⁹²Pirkanmaa Hospital District, Tampere, Finland, ²⁹³Department of Medicine, University of Cambridge, Cambridge, UK, ²⁹⁴South Karelia Central Hospital, Lappeenranta, Finland, ²⁹⁵Department of Psychology, University of Miami, Miami, FL, USA, ²⁹⁶Paul Langerhans Institute Dresden of the Helmholtz Center Munich, University Hospital and Faculty of Medicine, Dresden, Germany, ²⁹⁷Division of Population Health and Genomics, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK, ²⁹⁸Division of Sleep and Circadian Disorders, Brigham and Women's Hospital, Boston, MA, USA, ²⁹⁹Department of Public Health, Section of Epidemiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark, ³⁰⁰Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland, ³⁰¹Department of Aging and Health, Guy's and St Thomas' Foundation Trust, London, UK, ³⁰²Cardiovascular and Metabolic Disease Signature Research Program, Duke-NUS Medical School, Singapore, Singapore, ³⁰³Department of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland, ³⁰⁴Department of Public Health, University of Helsinki, Helsinki, Finland, ³⁰⁵Saudi Diabetes Research Group, King Abdulaziz University, Jeddah, Saudi Arabia, ³⁰⁶Department of Genomic Medicine and Environmental Toxicology, Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, ³⁰⁷Department of Public Health and Clinical Nutrition, University of Eastern Finland, Finland, ³⁰⁸Department of Medicine, Internal Medicine, Lausanne University Hospital (CHUV), Lausanne, Switzerland, ³⁰⁹Department of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA, ³¹⁰Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK, ³¹¹Beijing Tongren Eye Center, Beijing Key Laboratory of Intraocular Tumor Diagnosis and Treatment, Beijing Ophthalmology & Visual Sciences Key Lab, Beijing Tongren Hospital, Capital Medical University, Beijing, China, China, ³¹²Department of Public Health, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka, ³¹³Department of Research and Evaluation, Kaiser Permanente of Southern California, Pasadena, CA, USA, ³¹⁴Institute for Molecular Bioscience, The University of Queensland, Queensland, Australia, ³¹⁵Kurume University School of Medicine, Japan, ³¹⁶Wellcome Sanger Institute, Hinxton, UK, ³¹⁷TUM School of Medicine, Technical University of Munich and Klinikum Rechts der Isar, Munich, Germany, ³¹⁸Department of Pediatrics, Division of Endocrinology, Stanford School of Medicine, Stanford, CA, USA, ³¹⁹Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK, ³²⁰Department of Medicine, Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA, ³²¹Department of Medicine, General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA, ³²²Department of Medicine, Diabetes Unit and Endocrine Unit, Massachusetts General Hospital, Boston, MA, USA, ³²³Department of Human Genetics, University of Michigan, Ann Arbor, MI, USA, ³²⁴Centre for Genetics and Genomics Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, UK, ³²⁵Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester, UK, ³²⁶Department of Biostatistics, University of Liverpool, Liverpool, UK, ³²⁷University of Cambridge, Cambridge

DPP, DPPOS 1, DPPOS 2 & DPPOS 3A Research Group
(1996-2021)

Pennington Biomedical Research Center
(Baton Rouge, LA, USA)

George A. Bray, MD*
Kishore M. Gadde, MD*
Iris W. Culbert, BSN, RN, CCRC**
Annie Chatellier, RN, CCRC**
Jennifer Arceneaux RN, BSN**
Amber Dragg RD, LDN**
Catherine M. Champagne, PhD, RD
Crystal Duncan, LPN
Barbara Eberhardt, RD, LDN
Frank Greenway, MD
Fonda G. Guillory, LPN
April A. Herbert, RD
Michael L. Jeffirs, LPN
Betty M. Kennedy, MPA
Erma Levy, RD
Monica Lockett, LPN
Jennifer C. Lovejoy, PhD
Laura H. Morris, BS
Lee E. Melancon, BA, BS
Donna H. Ryan, MD
Deborah A. Sanford, LPN
Kenneth G. Smith, BS, MT
Lisa L. Smith, BS
Julia A. St.Amant, RTR
Richard T. Tulley, PhD
Paula C. Vicknair, MS, RD
Donald Williamson, PhD
Jeffery J. Zachwieja, PhD

University of Chicago (Chicago, IL, USA)

Kenneth S. Polonsky, MD*
Janet Tobian, MD, PhD*
David A. Ehrmann, MD*
Margaret J. Matulik, RN, BSN**
Karla A. Temple, PhD, RDN, LDN**
Bart Clark, MD
Kirsten Czech, MS
Catherine DeSandre, BA
Brittnie Dotson, MS
Ruthanne Hilbrich, RD
Wylie McNabb, EdD
Michael T. Quinn, PhD
Ann R. Semenske, MS, RD

Jefferson Medical College (Philadelphia, PA, USA)

Jose F. Caro, MD*
Pamela G. Watson, RN, ScD*

Barry J. Goldstein, MD, PhD*
Kevin Furlong, DO*
Kellie A. Smith, RN, MSN**
Jewel Mendoza, RN, BSN**
Wendi Wildman, RN**
Marsha Simmons, CCRP**
Genine Jensen, RN
Renee Liberoni, MPH
John Spandorfer, MD
Constance Pepe, MS, RD

University of Miami (Miami, FL, USA)

Richard P. Donahue, PhD*
Ronald B. Goldberg, MD*
Ronald Prineas, MD, PhD*
Patricia Rowe, MPA**
Anna Giannella, RD, MS**
Jeanette Calles, MSED**
Juliet Sanguily, RN**
Paul Cassanova-Romero, MD
Sumaya Castillo-Florez, MPH
Hermes J. Florez, MD
Rajesh Garg, MD
Lascelles Kirby, MS
Olga Lara
Carmen Larreal
Valerie McLymont, RN
Jadell Mendez
Arlette Perry, PhD
Patrice Saab, PhD
Bertha Veciana

The University of Texas Health Science Center
(San Antonio, TX, USA)

Steven M. Haffner, MD, MPH*
Helen P. Hazuda, PhD*
Maria G. Montez, RN, MSHP, CDE**
Juan Isaac, RN, BSN**
Kathy Hattaway, RD, MS
Carlos Lorenzo, MD, PhD
Arlene Martinez, RN, BSN, CDE
Monica Salazar
Tatiana Walker, RD, MS, CDE

University of Colorado (Denver, CO, USA)

Richard F. Hamman, MD, DrPH*
Dana Dabelea, MD, PhD*
Patricia V. Nash, MS**
Sheila C. Steinke, MS**
Lisa Testaverde, MS**
Jennifer Truong, MPH**

Denise R. Anderson, RN, BSN
 Larry B. Ballonoff, MD
 Alexis Bouffard, MA, RN, BSN
 Rebecca S. Boxer, MD, MS
 Brian Bucca OD, FAOO
 B. Ned Calonge, MD, MPH
 Lynne Delve
 Martha Farago, RN
 James O. Hill, PhD
 Shelley R. Hoyer, BS
 Tonya Jenkins, RD, CDE
 Bonnie T. Jortberg, MS, RD, CDE
 Dione Lenz, RN, BSN, CDE
 Marsha Miller, MS, RD
 Thomas Nilan, BS
 Leigh Perreault, MD
 David W. Price, MD
 Judith G. Regensteiner, PhD
 Emily B. Schroeder, MD
 Helen Seagle, MS, RD
 Carissa M. Smith, BS
 Brent VanDorsten, PhD
Joslin Diabetes Center (Boston, MA, USA)
 Edward S. Horton, MD*
 Medha Munshi, MD*
 Kathleen E. Lawton, RN**
 Catherine S. Poirier, RN, BSN**
 Kati Swift, RN, BSN**
 Sharon D. Jackson, CCRC,MS, RD, CDE**
 Ronald A. Arky, MD
 Marybeth Bryant
 Jacqueline P. Burke, BSN
 Enrique Caballero, MD
 Karen M. Callaphan, BA
 Barbara Fagnoli, RD
 Therese Franklin
 Om P. Ganda, MD
 Ashley Guidi, BS
 Mathew Guido, BA
 Alan M. Jacobsen, MD
 Lyn M. Kula, RD
 Margaret Kocal, RN, CDE
 Lori Lambert, MS, RD, LD
 Kathleen E. Lawton, RN
 Sarah Ledbury, Med, RD
 Maureen A. Malloy, BS
 Roeland J.W. Middelbeek, MD
 Maryanne Nicosia, MS, RD
 Cathryn F. Oldmixon, RN
 Jocelyn Pan, BS, MPH
 Marizel Quitingon
 Riley Rainville, BS

Stacy Rubtchinsky, BS
 Ellen W. Seely, MD
 Jessica Sansoucy, BS
 Dana Schweizer, BSN
 Donald Simonson, MD
 Fannie Smith, MD
 Caren G. Solomon, MD, MPH
 Jeanne Spellman, RD
 James Warram, MD
**VA Puget Sound Health Care System and
 University of Washington (Seattle, WA, USA)**
 Steven E. Kahn, MB, ChB*
 Brenda K. Montgomery, RN, BSN, CDE**
 Basma Fattaleh, BA**
 Celeste Colegrove, BS
 Wilfred Fujimoto, MD
 Robert H. Knopp, MD
 Edward W. Lipkin, MD
 Michelle Marr, BA
 Ivy Morgan-Taggart
 Anne Murillo, BS
 Kayla O'Neal, BS
 Dace Trence, MD
 Lonnesse Taylor, RN, BS
 April Thomas, RD, MPH, CDE
 Elaine C. Tsai, MD, MPH
University of Tennessee (Memphis, TN, USA)
 Abbas E. Kitabchi, PhD, MD, FACP*
 Samuel Dagogo-Jack, MD, MSc, FRCP, FACP*
 Mary E. Murphy, RN, MS, CDE, MBA**
 Laura Taylor, RN, BSN, CDE**
 Jennifer Dolgoff, RN, BSN**
 Ethel Faye Hampton, RN**
 William B. Applegate, MD, MPH
 Michael Bryer-Ash, MD
 Debra Clark, LPN
 Sandra L. Frieson, RN
 Uzoma Ibebuogu, MD
 Raed Imseis, MD
 Helen Lambeth, RN, BSN
 Lynne C. Lichtermann, RN, BSN
 Hooman Oktaei, MD
 Harriet Ricks
 Lily M.K. Rutledge, RN, BSN
 Amy R. Sherman, RD, LD
 Clara M. Smith, RD, MHP, LDN
 Judith E. Soberman, MD
 Beverly Williams-Cleaves, MD
 Avnisha Patel, MLT
 Ebenezer A. Nyenwe, MD, FACP
**Northwestern University's Feinberg School of
 Medicine (Chicago, IL, USA)**

Boyd E. Metzger, MD*
 Mark E. Molitch, MD*
 Amisha Wallia, MD*
 Mariana K. Johnson, MS, RN**
 Sarah VanderMolen, APN**
 Daphne T. Adelman, MBA, RN
 Catherine Behrends
 Michelle Cook, MS
 Marian Fitzgibbon, PhD
 Mimi M. Giles, MS, RD
 Monica Hartmuller, MSN, BSN
 Cheryl K.H. Johnson, MS, RN
 Diane Larsen, BS
 Anne Lowe, BS
 Megan Lyman, BS
 David McPherson, MD
 Samsam C. Penn, BA
 Thomas Pitts, MD
 Renee Reinhart, RN, MS
 Susan Roston, RN, RD
 Pamela A. Schinleber, RN, MS
Massachusetts General Hospital (Boston, MA, USA)
 David M. Nathan, MD*
 Charles McKittrick, BSN**
 Heather Turgeon, BSN**
 Mary Larkin, MSN**
 Marielle Mugford, BA**
 Nopporn Thangthaeng**
 Fernelle Leander**
 Kathy Abbott
 Ellen Anderson, MS, RD
 Laurie Bissett, MS, RD
 Kristy Bondi, BS
 Enrico Cagliero, MD
 Jose C. Florez, MD, PhD+
 Linda Delahanty, MS, RD
 Valerie Goldman, MS, RD
 Elaine Grassa
 Lindsey Gurry BSN, RN, CDE
 Kali D'Anna
 Fernelle Leandre BS
 Peter Lou, MD
 Alexandra Poulos
 Elyse Raymond, BS
 Valerie Ripley, BS
 Christine Stevens, RN
 Beverly Tseng
University of California-San Diego (La Jolla, CA, USA)
 Jerrold M. Olefsky, MD*
 Elizabeth Barrett-Connor, MD*

Sunder Mudaliar, MD*
 Maria Rosario Araneta, PhD*
 Mary Lou Carrion-Petersen, RN, BSN**
 Karen Vejvoda, RN, BSN, CDE, CCRC**
 Sarah Bassiouni, MPH
 Madeline Beltran, RN, BSN, CDE
 Lauren N. Claravall, BS
 Jonalle M. Dowden, BS
 Steven V. Edelman, MD
 Pranav Garimella, MBBS
 Robert R. Henry, MD
 Javiva Horne, RD
 Marycie Lamkin, RN
 Simona Szerdi Janesch, BA
 Diana Leos
 William Polonsky, PhD
 Rosa Ruiz
 Jean Smith, RN
 Jennifer Torio-Hurley
Columbia University (New York, NY, USA)
 F. Xavier Pi-Sunyer, MD*
 Blandine Laferrere, MD, PhD*
 Jane E. Lee, MS**
 Susan Hagamen, MS, RN, CDE**
 Kim Kelly-Dinham**
 David B. Allison, PhD
 Nnenna Agharanya
 Nancy J. Aronoff, MS, RD
 Maria Baldo
 Jill P. Crandall, MD
 Sandra T. Foo, MD
 Jose A. Luchsinger, MD, MPH
 Carmen Pal, MD
 Kathy Parkes, RN
 Mary Beth Pena, RN
 Julie Roman
 Ellen S. Rooney, BA
 Gretchen E.H. Van Wye, MA
 Kristine A. Viscovich, ANP
Indiana University (Indianapolis, IN, USA)
 Melvin J. Prince, MD*
 David G. Marrero, PhD*
 Kieren J. Mather, MD*
 Mary de Groot, PhD*
 Susie M. Kelly, RN, CDE**
 Marcia A. Jackson**
 Gina McAtee**
 Paula Putteney, RN**
 Ronald T. Ackermann, MD
 Carolyn M. Cantrell
 Yolanda F. Dotson, BS
 Edwin S. Fineberg, MD

Megan Fultz
John C. Guare, PhD
Angela Hadden
James M. Ignaut, MA
Marion S. Kirkman, MD
Erin O'Kelly Phillips
Kisha L Pinner
Beverly D. Porter, MSN
Paris J. Roach, MD
Nancy D. Rowland, BS, MS
Madelyn L. Wheeler, RD
Medstar Research Institute (Washington, DC, USA)

Robert E. Ratner, MD*
Vanita Aroda, MD*
Michelle Magee, MD*
Gretchen Youssef, RD, CDE**
Sue Shapiro, RN, BSN, CCRC**
Natalie Andon, RN
Catherine Bavidio-Arrage, MS, RD, LD
Geraldine Boggs, MSN, RN
Marjorie Bronsord, MS, RD, CDE
Ernestine Brown
Holly Love Burkott, RN
Wayman W. Cheatham, MD
Susan Cola
Cindy Evans
Peggy Gibbs
Tracy Kellum, MS, RD, CDE
Lilia Leon
Milvia Lagarda
Claresa Levatan, MD
Milajurine Lindsay
Asha K. Nair, BS
Jean Park, MD
Maureen Passaro, MD
Angela Silverman
Gabriel Uwaifo, MD
Debra Wells-Thayer, NP, CDE
Renee Wiggins, RD

University of Southern California/UCLA Research Center (Alhambra, CA, USA)

Mohammed F. Saad, MD*
Karol Watson, MD*
Maria Budget**
Sujata Jinagouda, MD**
Medhat Botrous, MD**
Anthony Sosa**
Sameh Tadros**
Khan Akbar, MD
Claudia Conzues
Perpetua Magpuri

Kathy Ngo
Amer Rassam, MD
Debra Waters
Kathy Xaphthalmous
Washington University (St. Louis, MO, USA)
Julio V. Santiago, MD*
Samuel Dagogo-Jack, MD, MSc, FRCP, FACP*
Neil H. White, MD, CDE*
Angela L. Brown, MD*
Ana Santiago, RN**
Samia Das, MS, MBA, RD, LD**
Prajakta Khare-Ranade, MSc, RDN, LD**
Tamara Stich, RN, MSN, CDE**
Edwin Fisher, PhD
Emma Hurt, RN
Jackie Jones
Tracy Jones, RN
Michelle Kerr, RD
Sherri McCowan
Lucy Ryder, RN
Cormarie Wernimont, RD, LD

Johns Hopkins School of Medicine (Baltimore, MD, USA)

Christopher D. Saudek, MD*
Sherita Hill Golden, MD, MHS, FAHA*
Vanessa Bradley, BA**
Emily Sullivan, MEd, RN**
Tracy Whittington, BS**
Caroline Abbas
Adrienne Allen
Frederick L. Brancati, MD, MHS
Sharon Cappelli
Jeanne M. Clark, MD
Jeanne B. Charleston, RN, MSN
Janice Freel
Katherine Horak, RD
Alicia Greene
Dawn Jiggetts
Delois Johnson
Hope Joseph
Rita Kalyani, MD, MHS
Kimberly Loman
Nestoras Mathioudakis, MD, MHS
Nisa Maruthur, MD, MHS
Henry Mosley
John Reusing
Richard R. Rubin, PhD
Alafia Samuels, MD
Thomas Shields
Shawne Stephens
Kerry J. Stewart, EdD
LeeLana Thomas

Evonne Utsey
Paula Williamson

University of New Mexico (Albuquerque, NM, USA)

David S. Schade, MD*
Karwyn S. Adams, RN, MSN**
Carolyn Johannes, RN, CDE**
Claire Hemphill, RN, BSN**
Penny Hyde, RN, BSN**
Janene L. Canady, RN, CDE**
Leslie F. Adler, PhD
Patrick J. Boyle, MD
Mark R. Burge, MD
Lisa Chai, RN
Kathleen Colleran, MD
Ateka Fondino
Ysela Gonzales
Doris A. Hernandez-McGinnis
Patricia Katz, LPN
Carolyn King, Med
Julia Middendorf, RN
Amer Rassam, MD
Sofya Rubinchik, MD
Willette Senter, RD
Debra Waters, PhD

Albert Einstein College of Medicine (Bronx, NY, USA)

Harry Shamoon, MD*
Jill Crandall, MD*
Janet O. Brown, RN, MPH, MSN**
Gilda Trandafirescu, MD**
Danielle Powell, MPH**
Elsie Adorno, BS
Liane Cox, MS, RD
Helena Duffy, MS, C-ANP
Samuel Engel, MD
Allison Friedler, BS
Angela Goldstein, FNP-C, NPP, CSW
Crystal J. Howard-Century, MA
Jennifer Lukin, BA
Stacey Kloiber, RN
Nadege Longchamp, LPN
Helen Martinez, RN, MSN, FNP-C
Dorothy Pompei, BA
Jonathan Scheindlin, MD
Norica Tomuta, MD
Elissa Violino, RD, MS
Elizabeth A. Walker PhD, RN
Judith Wylie-Rosett, EdD, RD
Elise Zimmerman, RD, MS
Joel Zonszein, MD

University of Pittsburgh (Pittsburgh, PA, USA)

Rena R. Wing, PhD*
Trevor Orchard, MD*
Elizabeth Venditti, PhD*
Gaye Koenning, MS, RD**
M. Kaye Kramer, BSN, MPH**
Marie Smith, RN, BSN**
Susan Jeffries, RN, MSN**
Valarie Weinzierl, MPH**
Susan Barr, BS
Catherine Benchoff
Miriam Boraz, PhD
Lisa Clifford, BS
Rebecca Culyba, BS
Marlene Frazier
Ryan Gilligan, BS
Stephanie Guimond, BS
Susan Harrier, MLT
Louann Harris, RN
Andrea Kriska, PhD
Qurashia Manjoo, MD
Monica Mullen, MHP, RD
Alicia Noel, BS
Amy Otto, PhD
Jessica Pettigrew, CMA
Bonny Rockette-Wagner, PhD
Debra Rubinstein, MD
Linda Semler, MS, RD
Cheryl F. Smith, PhD
Katherine V. Williams, MD, MPH
Tara Wilson, BA

University of Hawaii (Honolulu, HI, USA)

Richard F. Arakaki, MD*
Marjorie K. Mau, MD*
Renee W. Latimer, BSN, MPH**
Mae K. Isonaga, RD, MPH**
Narleen K. Baker-Ladao, BS**
Ralph Beddow, MD
Nina E. Bermudez, MS
Lorna Dias, AA
Jillian Inouye, RN, PhD
John S. Melish, MD
Kathy Mikami, BS, RD
Pharis Mohideen, MD
Sharon K. Odom, RD, MPH
Raynette U. Perry, AA
Robin E. Yamamoto, CDE, RD

Southwest American Indian Centers (Phoenix, AZ; Shiprock, NM; Zuni, NM, USA)

William C. Knowler, MD, DrPH*
Robert L. Hanson, MD, MPH*
Vallabh Shah, PhD*

Mary A. Hoskin, RD, MS**
Carol A. Percy, RN, MS**
Norman Coeoyate**
Camille Natewa**
Charlotte Dodge**
Alvera Enote, RD**
Harelda Anderson, LMSW**
Kelly J. Acton, MD, MPH
Vickie L. Andre, RN, FNP
Rosalyn Barber
Shandiin Begay, MPH
Peter H. Bennett, MB, FRCP
Mary Beth Benson, RN, BSN
Evelyn C. Bird, RD, MPH
Brenda A. Broussard, RD, MPH, MBA, CDE
Brian C. Bucca, OD, FAAO
Marcella Chavez, RN, AS
Sherron Cook
Jeff Curtis, MD
Tara Dacawyma
Matthew S. Doughty, MD
Roberta Duncan, RD
Cyndy Edgerton, RD
Jacqueline M. Ghahate
Justin Glass, MD
Martia Glass, MD
Dorothy Gohdes, MD
Wendy Grant, MD
Ellie Horse
Louise E. Ingraham, MS, RD, LN
Merry Jackson
Priscilla Jay
Roylen S. Kaskalla
Karen Kavena, ANP
David Kessler, MD
Kathleen M. Kobus, RNC-ANP
Jonathan Krakoff, MD
Jason Kurland, MD
Catherine Manus, LPN
Cherie McCabe
Sara Michaels, MD
Tina Morgan
Yolanda Nashboo
Julie A. Nelson, RD
Steven Poirier, MD
Evette Polczynski, MD
Christopher Piromalli, DO
Mike Reidy, MD
Jeanine Roumain, MD, MPH
Debra Rowse, MD
Robert J. Roy
Sandra Sangster, RD

Janet Sewenemewa
Miranda Smart
Chelsea Spencer
Darryl Tonemah, PhD
Rachel Williams, FNP
Charlton Wilson, MD
Michelle Yazzie
**George Washington University Biostatistics
Center (DPP Coordinating Center Rockville, MD,
USA)**
Raymond Bain, PhD*
Sarah Fowler, PhD*
Michael D. Larsen, PhD*
Kathleen Jablonski, PhD*
Marinella Temprosa, PhD*
Tina Brennehan**
Sharon L. Edelstein, ScM**
Solome Abebe, MS
Julie Bamdad, MS
Melanie Barkalow
Joel Bethedu, MS
Tsedenia Bezabeh, MS
Anna Bowers
Nicole Butler, MPH
Jackie Callaghan
Caitlin E. Carter, MPH
Costas Christophi, PhD
Gregory M. Dwyer, MPH
Mary Foulkes, PhD
Yuping Gao
Robert Gooding
Adrienne Gottlieb, MS
Kristina L. Grimes
Nisha Grover-Fairchild, MPH
Lori Haffner, MS
Heather Hoffman, PhD
Steve Jones
Tara L. Jones
Richard Katz, MD
Preethy Kolinjivadi, MS
John M. Lachin, ScD
Yong Ma, PhD
Pamela Mucik
Robert Orlosky
Qing Pan, PhD
Susan Reamer, MS
James Rochon, PhD
Alla Sapozhnikova, PhD
Hanna Sherif, MS
Charlotte Stimpson
Ashley Hogan Tjaden, MPH
Fredricka Walker-Murray

Lifestyle Resource Core (Pittsburgh, PA, USA)

Elizabeth M. Venditti, PhD*

Andrea M. Kriska, PhD

Linda Semler, MS, RD, LDN

Valerie Weinzierl, MPH

Central Biochemistry Laboratory (Seattle, WA, USA)

Santica Marcovina, PhD, ScD*

F. Alan Aldrich**

Jessica Harting**

John Albers, PhD

Greg Strylewicz, PhD

Advanced Research Diagnostic Laboratory (Minneapolis, MN, USA)

Anthony Killeen, MD, PhD*

Deanna Gabrielson**

NIH/NIDDK (Bethesda, MD, USA)

R. Eastman, MD

Judith Fradkin, MD

Sanford Garfield, PhD

Christine Lee, MD, MS

Centers for Disease Control & Prevention

(Atlanta, GA, USA)

Edward Gregg, PhD

Ping Zhang, PhD

Carotid Ultrasound (Boston, MA, USA)

Dan O'Leary, MD*

Gregory Evans

Coronary Artery Calcification Reading Center

(Torrence, CA, USA)

Matthew Budoff, MD

Chris Dailing

CT Scan Reading Center (Denver, CO, USA)

Elizabeth Stamm, MD*

Dual Energy X-ray Absorptiometry Reading

Center (San Francisco, CA, USA)

Ann Schwartz, PhD

Caroline Navy

Lisa Palermo, MS

Epidemiological Cardiology Research Center-

Epicare (Winston-Salem, NC, USA)

Pentti Rautaharju, MD, PhD*

Ronald J. Prineas, MD, PhD**

Elsayed Z. Soliman, MD*

Teresa Alexander

Charles Campbell, MS

Sharon Hall

Yabing Li, MD

Margaret Mills

Nancy Pemberton, MS

Farida Rautaharju, PhD

Zhuming Zhang, MD

Julie Hu, MSc

Susan Hensley, BS

Lisa Keasler

Tonya Taylor

Fundus Photo Reading Center (Madison, WI, USA)

Ronald Danis, MD*

Matthew Davis, MD*

Larry Hubbard*

Barbara Blodi, MD*

Ryan Endres**

Deborah Elsas**

Samantha Johnson**

Dawn Myers**

Nancy Barrett

Heather Baumhauer

Wendy Benz

Holly Cohn

Ellie Corkery

Kristi Dohm

Amitha Domalpally, MD, PhD

Vonnie Gama

Anne Goulding

Andy Ewen

Cynthia Hurtenbach

Daniel Lawrence

Kyle McDaniel

Jeong Pak

James Reimers

Ruth Shaw

Maria Swift

Pamela Vargo, CRA

Sheila Watson

Neurocognitive Assessment Group (New York, NY, USA)

Jose A. Luchsinger, MD, MPH

Jennifer Manly, PhD

Nutrition Coding Center (Columbia, SC, USA)

Elizabeth Mayer-Davis, PhD*

Robert R. Moran, PhD**

Quality of Well-Being Center (La Jolla, CA, USA)

Ted Ganiats, MD*

Kristin David, MHP*

Andrew J. Sarkin, PhD*

Erik Groessl, PhD

Naomi Katzir

Helen Chong, MA

University of Michigan (Ann Arbor, MI, USA)

William H. Herman, MD, MPH

Michael Brändle, MD, MS

Morton B. Brown, PhD

Genetics Working Group

Jose C. Florez, MD, PhD^{1, 2}
David Altshuler, MD, PhD^{1, 2}
Liana K. Billings, MD¹
Ling Chen, MS¹
Maegan Harden, BS²
Robert L. Hanson, MD, MPH³
William C. Knowler, MD, DrPH³
Toni I. Pollin, PhD⁴
Alan R. Shuldiner, MD⁴
Kathleen Jablonski, PhD⁵
Paul W. Franks, PhD, MPhil, MS^{6, 7, 8}
Marie-France Hivert, MD¹
Josephine H. Li, MD^{1, 2}
James A. Perry, PhD⁴
Shylaja Srinivasan, MD⁹
Josep M. Mercader, PhD^{1, 2}

Jennifer N. Todd, MD¹⁰

1=Massachusetts General Hospital, Boston, MA, USA
2=Broad Institute, Boston, MA, USA
3=NIDDK, Bethesda, MD, USA
4=University of Maryland, College Park, MD, USA
5=Coordinating Center, Rockville, MD, USA
6=Lund University, Sweden
7=Umeå University, Sweden
8=Harvard School of Public Health, Boston, MA, USA
9=University of California at San Francisco, San Francisco, CA, USA
10=University of Vermont, Burlington, VT, USA
* denotes Principal Investigator
** denotes Program Coordinator

ESM Methods

Study Design of SUGAR-MGH

SUGAR-MGH is an NIH-funded pharmacogenetic study in 1,000 adults at three Boston medical centers from 2008-2015. Subjects were enrolled if they had never been on anti-diabetes medications; they could have a family history or personal history of diabetes that was lifestyle or diet-controlled. At Visit 1 (V1), a single dose of glipizide was administered in the fasting state with plasma glucose and insulin measured at regular intervals up to 240 minutes. After a washout period, participants received 500 mg of metformin twice daily for two days and, at Visit 2 (V2) a week later, a 75-g oral glucose tolerance test (OGTT) with glucose and insulin measurements. A subset had glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), proinsulin, and glucagon measured.

Colocalization Methods

The COLOC 4.0 R package [1] was used for the colocalization analysis. We used the coloc.abf method which implements a variation of the Approximate Bayes Factor computations [2]. The coloc.abf function was called with two R lists, one for the SUGAR-MGH and one for the T2D/glycemic trait GWAS: list(pvalues=..., N=..., MAF=..., snp=..., type="quant"), with a vector of p -values, N for the sample size, MAF for the minor allele frequency, and snp for the rsid of the variant. The colocalization was run over regions ranging from one million base pairs downstream to one million upstream from the lead SUGAR-MGH variant. We reported the posterior probabilities (PP) of colocalization. The colocalization plots were generated using the locuscompare R package v1.0.0 [3].

Replication of genome-wide significant variants associated with metformin response in the Diabetes Prevention Program (DPP)

Description of participants and DPP study design

The study design and baseline characteristics of the participants in the DPP have been previously published [4, 5]. A total of 3,819 individuals were randomized to intensive lifestyle modification (goal weight loss $\geq 7\%$ and ≥ 150 min/week of physical activity), standard lifestyle recommendations plus metformin (850 mg twice daily), standard lifestyle recommendations plus troglitazone (400 mg daily), or standard lifestyle recommendations plus placebo. The primary endpoint of the DPP was diabetes incidence, defined as a fasting glucose of ≥ 126 mg/dL (7.0 mmol/L) or a 2-hour glucose of ≥ 200 mg/dL (11.1 mmol/L) after OGTT and confirmed on a second test within 6 weeks.

Institutional review board approval was obtained by each participating clinical center. For the genome-wide association study (GWAS) of metformin response completed in the DPP [6], all participants included provided written informed consent for the main investigation and for genetic studies.

Genome-wide genotyping and quality control

DNA was extracted from peripheral blood leukocytes. A total of 3,227 samples underwent genotyping on the HumanCore Exome genome-wide array (Illumina, San Diego, CA). Single nucleotide polymorphisms were excluded with a call rate $< 95\%$ or if they failed Hardy-Weinberg Equilibrium (HWE; $p < 1.0 \times 10^{-8}$) within each ethnic group. Samples with discrepant sex, call rate $< 95\%$, inbreeding coefficient < -1 , and identity-by-state as measured by π -hat close to 1 were discarded. Since 9,730 SNPs and 3,222 samples were also genotyped on the MetaboChip (Illumina, San Diego, CA), a concordance check was performed, excluding SNPs and samples with a concordance rate $< 95\%$. A total of 3,168 samples remained after all quality checks were completed.

Imputation

A two-stage imputation procedure was performed, which involved pre-phasing the genotypes into whole chromosome haplotypes and then performing imputation. The pre-phasing was done using SHAPEIT2 [7] and imputation utilized IMPUTE2 [8]. GWIMp-COMPSs, [9] which can incorporate the contribution of several reference panels, was employed using 1000 Genomes Phase3 haplotypes (October 2014) [10].

Statistical analyses

The metformin GWAS in the DPP examined both the primary outcome of diabetes incidence, as well as the one-year change in quantitative traits relevant to metformin action, which included fasting glucose, 2-hour glucose after 75-g OGTT, fasting insulin, insulin sensitivity index (ISI), hemoglobin A1c (HbA1c), and weight.

For the quantitative trait analysis, a multiple linear regression model tested allelic associations with each quantitative outcome, assuming an additive model. One-year change in each quantitative outcome was defined as one-year minus baseline value. Non-normally distributed traits were natural log transformed. To minimize the influence of outliers, winsorization was performed (at percentiles of 0.5 and 99.5 for normally distributed traits; percentiles of 1 and 99 for natural log transformed traits) [11]. Analyses were adjusted for age, sex, first 10 ancestry principal components, and the baseline trait. For each of the six outcomes, the impact of genetic variation was evaluated in the metformin arm only, and in a second model, with a gene-by-treatment interaction for the metformin and placebo arms. GWAS results in the DPP were filtered to a study-wide MAF>1% and imputation quality ≥ 0.7 .

As described in the main manuscript, for the replication of SUGAR-MGH findings, we limited our analysis to one-year change in fasting glucose and HbA1c in the metformin arm only.

ESM Table 1. List of secondary outcomes of metformin and glipizide response in SUGAR-MGH and the drug response

Glucose at 30 mins at V1 +/- adjustment for baseline glucose V1 (glipizide)
Glucose at 60 mins at V1 +/- adjustment for baseline glucose V1 (glipizide)
Glucose at 90 mins at V1 +/- adjustment for baseline glucose V1 (glipizide)
Glucose at 120 mins at V1 +/- adjustment for baseline glucose V1 (glipizide)
Glucose at 180 mins at V1 +/- adjustment for baseline glucose V1 (glipizide)
Glucose at 240 mins at V1 +/- adjustment for baseline glucose V1 (glipizide)
Glucose at 30 mins at V2 +/- adjustment for baseline glucose V2 (metformin)
Glucose at 60 mins at V2 +/- adjustment for baseline glucose V2 (metformin)
Glucose at 120 mins at V2 +/- adjustment for baseline glucose V2 (metformin)
Area under the curve of insulin at V2 adjusted for fasting insulin at V2 (metformin)
Fasting glucose at V2 minus fasting glucose at V1 +/- adjustment for baseline glucose V1 (metformin)
Fasting insulin at V2 minus fasting insulin at V1 +/- adjustment for baseline insulin V1 (metformin)
HOMA-IR at V2 minus HOMA-IR at V1 (metformin)
HOMA-B at V2 minus HOMA-B at V1 (metformin)
Insulin at 30 mins at V1 (glipizide)
Insulin at 60 mins at V1 (glipizide)
Insulin at 90 mins at V1 (glipizide)
Insulin at 120 mins at V1 (glipizide)
Insulin at 180 mins at V1 (glipizide)
Insulin at 240 mins at V1 (glipizide)
Fasting insulin at V2 (metformin)
Insulin at 30 mins at V2 (metformin)
Insulin at 60 mins at V2 (metformin)
Insulin at 120 mins at V2 (metformin)
Slope to glucose trough at V1 +/- adjustment for baseline glucose (glipizide)
Slope to glucose recovery at V1 +/- adjustment for baseline glucose (glipizide)
Slope to insulin peak at V1 +/- adjustment for baseline insulin V1 (glipizide)
Time to reach peak insulin at V1 +/- adjustment for baseline insulin V1 (glipizide)

ESM Table 2. Demographic characteristics and baseline measurements of 890 participants with genome-wide genotyping in SUGAR-MGH.

	All participants (n=890)
Women [n (%)]	474 (53.3)
Age (years)	47.1 ± 16.2
BMI (kg/m ²) (n=873)	30.2 ± 7.2
Self-reported race/ethnicity [n (%)]	
White, non-Hispanic	560 (62.9)
Black, non-Hispanic	190 (21.4)
Hispanic	63 (7.1)
Asian, non-Hispanic	53 (5.9)
Others	24 (2.7)
Diagnosis of T2D [n (%)]	22 (2.8)
Received full glipizide challenge	572 (64.3)
Fasting glucose (mmol/L)	5.1 ± 0.9
Fasting insulin (pmol/L)	41.9 (42.1)
HOMA-B	91.3 ± 131.8

Age, body mass index (BMI), fasting glucose, and homeostasis model assessment of β -cell function (HOMA-B) are mean \pm SD. Fasting insulin is median (interquartile range).

ESM Table 3. Genotype counts by self-reported race/ethnicity of the five genome-wide significant variants ($p < 5 \times 10^{-8}$) associated with primary endpoints of acute metformin or glipizide response in SUGAR-MGH.

	rs149403252			rs111770298			rs117207651			rs9954585			rs150628520		
	GG	GT	TT	AA	AG	GG	TT	TC	CC	CC	CT	TT	AA	AG	GG
White, non-Hispanic	515	0	0	515	0	0	506	9	0	378	2	0	375	5	0
Black, non-Hispanic	159	8	0	150	17	0	166	1	0	89	10	0	99	0	0
Hispanic	57	1	0	56	2	0	58	0	0	34	1	0	34	1	0
Asian, non-Hispanic	43	0	0	43	0	0	43	0	0	24	0	0	23	1	0
Others	22	0	0	20	2	0	21	1	0	11	1	0	12	0	0

For all imputed variants, fractional alleles were converted to hard calls for calculation of genotype counts.

ESM Table 4. Replication of genome-wide significant variants associated with metformin response in the DPP.

rsid	Chr	Position ^a	Nearest Gene	NEA	EA	EAF ^b	AfrAm ^c	AsnPI ^c	Hispc ^c	AI ^c	White ^c	N	Trait	Beta (95% CI)	p-value
rs149403252	3	55883717	<i>ERC2</i>	G	T	0.0082	0.0263	0.0001	0.0023	0.0001	0.0003	821	Fasting glucose, mmol/L	-0.17 (-0.45, 0.10)	0.22
rs149403252	3	55883717	<i>ERC2</i>	G	T	0.0082	0.0263	0.0001	0.0023	0.0001	0.0003	818	HbA1c, %	0.04 (-0.11, 0.19)	0.61
rs111770298	2	28307503	<i>BABAM2/ FOSL2</i>	A	G	0.0145	0.0586	<0.0001	0.0028	<0.0001	0.0003	821	Fasting glucose, mmol/L	0.003 (-0.20, 0.21)	0.98
rs111770298	2	28307503	<i>BABAM2/ FOSL2</i>	A	G	0.0145	0.0586	<0.0001	0.0028	<0.0001	0.0003	818	HbA1c, %	0.17 (0.06, 0.29)	3.31×10⁻³
rs117207651	16	82250950	<i>MPHOSPH6</i>	T	C	0.0124	0.0026	0.0001	0.0092	<0.0001	0.0149	821	Fasting glucose, mmol/L	0.11 (-0.13, 0.36)	0.37
rs117207651	16	82250950	<i>MPHOSPH6</i>	T	C	0.0124	0.0026	0.0001	0.0092	<0.0001	0.0149	818	HbA1c, %	0.02 (-0.11, 0.16)	0.74

NEA=Non-effect allele; EA=Effect allele; EAF=Effect allele frequency; AfrAm=African American; AsnPI= Asian Pacific Islander; AI=American Indian; ^aGRCh38 assembly. ^bThis is the effect allele frequency for the number of participants in the model (N) that was calculated based on imputation. ^cEffect allele frequency breakdown by self-reported race/ethnicity is for all 3,168 participants in the DPP with genome-wide genotyping, calculated based on imputation.

ESM Table 5. Genome-wide significant variants ($p < 5 \times 10^{-8}$) associated with multiple drug response endpoints in SUGAR-MGH.

rsid	Chr	Position ^a	Nearest gene	NEA	EA	EAF	AFR ^b	AMR ^b	EAS ^b	EUR ^b	SAS ^b	N	Trait (drug)	Beta ^c	p-value	Additional traits
rs150628520 ^d	4	187296094	<i>FAT1</i>	A	G	0.009	0.002	0.007	0.0002	0.011	0.002	550	Time to reach glucose trough at V1 (glipizide)	1.7	9.7×10^{-9}	Slope to glucose trough at V1 (beta=-1.7, $p=7.3 \times 10^{-8}$)
rs111406936	10	113583078	<i>HABP2</i>	A	T	0.008	0.031	0.003	0	0.0002	0	776	Insulin at 60 mins at V2 (metformin)	-1.5	6.4×10^{-9}	AUC insulin at V2 (beta=-1.4, $p=7.2 \times 10^{-7}$)
rs149193557	3	98379904	<i>OR5K3</i>	A	C	0.013	0.0598	0.008	0	0.0003	0	545	AOC glucose at V1 (glipizide)	-1.3	1.1×10^{-8}	Glucose trough at V1 (beta=-1.3, $p=3.0 \times 10^{-6}$)
rs111770298 ^d	2	28307503	<i>BABAM2/ FOSL2</i>	A	G	0.013	0.054	0.005	0	0.0001	0.0002	807	Fasting glucose at V2 adj. V1 (metformin)	0.7	2.4×10^{-8}	Fasting glucose at V2-fasting glucose at V1 (beta=1.1, $p=2.7 \times 10^{-7}$)
rs2749695	1	225964122	<i>LEFTY1, SDE2</i>	T	A	0.628	0.580	0.542	0.776	0.623	0.669	807	Insulin at 30 mins at V1 (glipizide)	0.3	3.2×10^{-8}	Insulin at 60 min at V1 (beta=0.2, $p=1.8 \times 10^{-6}$)
rs146209333	3	64193613	<i>PRICKLE2</i>	T	C	0.012	0.002	0.005	0	0.014	0.003	830	Glucose at 60 mins at V1 (glipizide)	-0.9	3.3×10^{-8}	Slope to glucose trough at V1 (beta=1.2, $p=9.9 \times 10^{-8}$), Glucose trough at V1 (beta=-0.9, $p=2.8 \times 10^{-6}$)
rs12062755	1	182077342	<i>ZNF648</i>	G	A	0.113	0.124	0.139	0.280	0.122	0.227	794	Glucose at 60 mins at V2 (metformin)	0.4	4.4×10^{-8}	AUC glucose at V2 (beta=0.42, $p=5.7 \times 10^{-8}$)

NEA=Non-effect allele; EA=Effect allele; EAF=Effect allele frequency; AFR=African; AMR=Admixed American; EAS=East Asian; EUR=European; SAS=South Asian; V1=Visit 1, glipizide visit; V2=Visit 2, metformin visit; AOC=area over the curve; AUC=area under the curve. ^aGRCh38 assembly.

^bAncestry-specific allele frequencies as reported by gnomAD 3.1.2 ^cBeta estimates are rank-inverse normalized. ^dVariant present in Table 1.

ESM Table 6. Known genome-wide significant T2D and glycemic variation that meet screening threshold ($p < 8.9 \times 10^{-5}$) in SUGAR-MGH for subsequent colocalization analyses.

rsid	Chr	Position ^a	Nearest gene	NEA	EA	EAF ^b	OR (95% CI) ^b	T2D <i>p</i> -value ^b		SUGAR-MGH trait (drug)	N	Beta ^c	<i>p</i> -value	PP result
rs703972	10	79193069	<i>ZMIZ1</i>	G	C	0.467	0.93 (0.92-0.94)	1.7×10^{-29}		Active GLP-1 at 30 min at V2 (metformin)	143	0.5	1.6×10^{-5}	90.3
rs9828772	3	129614339	<i>TMCC1</i>	C	G	0.102	0.94 (0.93-0.96)	4.2×10^{-8}		Fasting glucagon at V1 (glipizide)	492	0.4	2.1×10^{-5}	76.8
rs6070625	20	58819573	<i>GNAS</i>	C	G	0.517	1.05 (1.04-1.06)	5.3×10^{-14}		Fasting glucose at V2 minus fasting glucose at V1 (metformin)	805	0.2	2.9×10^{-5}	96.6
rs11688682	2	120590036	<i>GLI2</i>	G	C	0.272	0.95 (0.94-0.97)	4.2×10^{-9}		Active GLP-1 at 5 min at V2 (metformin)	144	0.6	3.1×10^{-5}	70.9
rs12048743	1	205145745	<i>DSTYK</i>	C	G	0.442	1.04 (1.03-1.05)	3.5×10^{-9}		Fasting glucose at V2 minus fasting glucose at V1 (metformin)	805	-0.2	8.2×10^{-5}	89.7
rs7903146	10	112998590	<i>TCF7L2</i>	C	T	0.294	1.37 (1.35-1.39)	6.0×10^{-447}		Total GLP-1 at 10 min at V2 (metformin)	142	0.4	8.8×10^{-5}	79.7
rsid	Chr	Position	Nearest gene	NEA	EA	EAF*	Beta (SE)*	MAGIC <i>p</i> -value*	MAGIC trait	SUGAR-MGH trait	N	Beta	<i>p</i> -value	PP result
rs8914	11	46677574	<i>ATG13</i>	G	A	0.108	-0.040 (0.006)	4.1×10^{-13}	Fasting glucose	Fasting glucose at V1 (without drugs)	851	-0.3	6.8×10^{-6}	1.9
rs8914	11	46677574	<i>ATG13</i>	G	A	0.108	-0.040 (0.006)	4.1×10^{-13}	Fasting glucose	Glucose at 30 min at V1 (glipizide)	832	-0.3	2.3×10^{-5}	1.7
rs8914	11	46677574	<i>ATG13</i>	G	A	0.108	-0.040 (0.006)	4.1×10^{-13}	Fasting glucose	Fasting glucose at V2 (metformin)	807	-0.3	4.9×10^{-5}	1.6
rs2745353	6	127131790	<i>RSPO3</i>	C	T	0.516	0.031 (0.004)	4.6×10^{-16}	Fasting insulin	Insulin peak at V1 (glipizide)	830	0.2	7.7×10^{-5}	91.0
rs2971669	7	44192179	<i>GCK</i>	C	T	0.202	0.083 (0.008)	3.8×10^{-28}	2-hour glucose	Fasting glucose at V2 (metformin)	807	0.2	8.6×10^{-5}	76.8
rs7903146	10	112998590	<i>TCF7L2</i>	C	T	0.275	0.047 (0.004)	2.0×10^{-35}	Fasting glucose	Total GLP-1 at 10 min at V2 (metformin)	142	0.4	8.8×10^{-5}	77.0


rs7903146	10	112998590	<i>TCF7L2</i>	C	T	0.278	-0.027 (0.005)	1.2×10 ⁻⁹	Fasting insulin	Total GLP-1 at 10 min at V2 (metformin)	142	0.4	8.8×10 ⁻⁵	74.6
rs7903146	10	112998590	<i>TCF7L2</i>	C	T	0.281	0.043 (0.004)	1.0×10 ⁻²²	HbA1c	Total GLP-1 at 10 min at V2 (metformin)	142	0.4	8.8×10 ⁻⁵	79.4
rs7903146	10	112998590	<i>TCF7L2</i>	C	T	0.259	0.070 (0.007)	2.8×10 ⁻²⁶	2-hour glucose	Total GLP-1 at 10 min at V2 (metformin)	142	0.4	8.8×10 ⁻⁵	80.0

NEA=Non-effect allele; EA=Effect allele; EAF=Effect allele frequency; PP=posterior probability; MAGIC=Meta-Analysis of Glucose and Insulin-related traits Consortium. ^aGRCh38 assembly. ^bDenote results from T2D GWAS and MAGIC. ^cBeta estimates are rank-inverse normalized.



ESM Table 7. Association of polygenic scores with the primary endpoints of metformin and glipizide response in SUGAR-MGH

SUGAR-MGH Outcome	Beta	SD	p-value	Polygenic score tested	Reference
Fasting glucose at V2, adj. V1 (metformin)	0.091	0.029	0.0018	gePS for fasting glucose	Chen et al. 2021
Time to reach glucose trough (glipizide)	-0.082	0.038	0.031	obesity cluster (pPS)	Udler et al. 2018
Glucose trough adj. baseline glucose (glipizide)	0.187	0.094	0.048	gePS for type 2 diabetes	Mahajan et al. 2020; Vujkovic et al. 2020
Fasting glucose at V2, adj. V1 (metformin)	0.1	0.057	0.076	gePS for type 2 diabetes	Mahajan et al. 2020; Vujkovic et al. 2020
Time to reach glucose trough (glipizide)	0.089	0.05	0.078	gePS for fasting glucose	Chen et al. 2021
Fasting glucose at V2, adj. V1 (metformin)	0.048	0.029	0.11	gePS for HbA1c	Chen et al. 2021
Peak insulin, adj. baseline insulin (glipizide)	0.045	0.03	0.14	obesity cluster (pPS)	Udler et al. 2018
Fasting glucose at V2, adj. V1 (metformin)	-0.031	0.023	0.17	beta cell cluster (pPS)	Udler et al. 2018
Time to reach glucose trough (glipizide)	0.07	0.053	0.19	gePS for fasting insulin	Chen et al. 2021
Time to reach glucose trough (glipizide)	0.121	0.098	0.22	gePS for type 2 diabetes	Mahajan et al. 2020; Vujkovic et al. 2020
Peak insulin, adj. baseline insulin (glipizide)	-0.039	0.032	0.22	liver/lipid cluster (pPS)	Udler et al. 2018
Fasting glucose at V2, adj. V1 (metformin)	0.035	0.03	0.25	gePS for fasting insulin	Chen et al. 2021
Time to reach glucose trough (glipizide)	0.058	0.051	0.26	gePS for HbA1c	Chen et al. 2021
Glucose trough adj. baseline glucose (glipizide)	0.034	0.037	0.37	liver/lipid cluster (pPS)	Udler et al. 2018
Glucose trough adj. baseline glucose (glipizide)	0.033	0.036	0.37	obesity cluster (pPS)	Udler et al. 2018
Peak insulin, adj. baseline insulin (glipizide)	0.036	0.041	0.38	gePS for HbA1c	Chen et al. 2021
Fasting glucose at V2, adj. V1 (metformin)	-0.019	0.023	0.41	liver/lipid cluster (pPS)	Udler et al. 2018
Fasting glucose at V2, adj. V1 (metformin)	0.018	0.023	0.43	obesity cluster (pPS)	Udler et al. 2018
Peak insulin, adj. baseline insulin (glipizide)	0.035	0.043	0.43	gePS for fasting insulin	Chen et al. 2021
Glucose trough adj. baseline glucose (glipizide)	0.028	0.037	0.45	lipodystrophy cluster (pPS)	Udler et al. 2018
Fasting glucose at V2, adj. V1 (metformin)	0.015	0.024	0.53	proinsulin cluster (pPS)	Udler et al. 2018
Glucose trough adj. baseline glucose (glipizide)	0.029	0.05	0.57	gePS for fasting glucose	Chen et al. 2021
Peak insulin, adj. baseline insulin (glipizide)	0.015	0.032	0.63	lipodystrophy cluster (pPS)	Udler et al. 2018
Peak insulin, adj. baseline insulin (glipizide)	-0.014	0.031	0.65	beta cell cluster (pPS)	Udler et al. 2018
Time to reach glucose trough (glipizide)	0.017	0.039	0.67	lipodystrophy cluster (pPS)	Udler et al. 2018
Glucose trough adj. baseline glucose (glipizide)	0.019	0.051	0.7	gePS for fasting insulin	Chen et al. 2021
Glucose trough adj. baseline glucose (glipizide)	0.011	0.037	0.77	beta cell cluster (pPS)	Udler et al. 2018
Glucose trough adj. baseline glucose (glipizide)	-0.011	0.041	0.79	proinsulin cluster (pPS)	Udler et al. 2018
Time to reach glucose trough (glipizide)	0.009	0.039	0.82	liver/lipid cluster (pPS)	Udler et al. 2018
Peak insulin, adj. baseline insulin (glipizide)	-0.008	0.034	0.82	proinsulin cluster (pPS)	Udler et al. 2018
Time to reach glucose trough (glipizide)	-0.009	0.042	0.84	proinsulin cluster (pPS)	Udler et al. 2018
Peak insulin, adj. baseline insulin (glipizide)	0.007	0.041	0.87	gePS for fasting glucose	Chen et al. 2021
Peak insulin, adj. baseline insulin (glipizide)	-0.013	0.079	0.87	gePS for type 2 diabetes	Mahajan et al. 2020; Vujkovic et al. 2020
Fasting glucose at V2, adj. V1 (metformin)	-0.002	0.023	0.93	lipodystrophy cluster (pPS)	Udler et al. 2018
Glucose trough adj. baseline glucose (glipizide)	0.004	0.049	0.93	gePS for HbA1c	Chen et al. 2021
Time to reach glucose trough (glipizide)	-0.001	0.039	0.97	beta cell cluster (pPS)	Udler et al. 2018




gePS=global extended polygenic score; pPS=process-specific polygenic score




ESM Fig. 1. (a) Regional association plot of rs149403252. (b) Box plot illustrating mean change in fasting glucose (Visit 2 minus Visit 1) by rs149403252 genotype.



ESM Fig 2. (a) Regional association plot of rs117207651. (b) Box plot illustrating mean change in fasting glucose (Visit 2 minus Visit 1) by rs117207651 genotype.



ESM Figure 3. (a) Regional association plot of rs9954585. (b) Change in plasma glucose by rs9954585 genotype at Visit 1 after glipizide administration. (c) Change in plasma insulin by rs9954585 genotype at Visit 1 after glipizide administration.



ESM Fig. 4. (a) Regional association plot of rs150628520. (b) Change in plasma glucose by rs150628520 genotype at Visit 1 after glipizide administration. (c) Change in plasma insulin by rs150628520 genotype at Visit 1 after glipizide administration.

References

- [1] Giambartolomei C, Zhenli Liu J, Zhang W, et al. (2018) A Bayesian framework for multiple trait colocalization from summary association statistics. *Bioinformatics (Oxford, England)* 34(15): 2538-2545. 10.1093/bioinformatics/bty147
- [2] Wakefield J (2009) Bayes factors for genome-wide association studies: comparison with P-values. *Genet Epidemiol* 33(1): 79-86. 10.1002/gepi.20359
- [3] Liu B, Gloudemans MJ, Rao AS, Ingelsson E, Montgomery SB (2019) Abundant associations with gene expression complicate GWAS follow-up. *Nat Genet* 51(5): 768-769. 10.1038/s41588-019-0404-0
- [4] The Diabetes Prevention Program (1999) Design and methods for a clinical trial in the prevention of type 2 diabetes. *Diabetes care* 22(4): 623-634. 10.2337/diacare.22.4.623
- [5] The Diabetes Prevention Program Research Group (2000) The Diabetes Prevention Program: baseline characteristics of the randomized cohort. *Diabetes care* 23(11): 1619-1629. 10.2337/diacare.23.11.1619
- [6] Li JH, Perry JA, Jablonski KA, et al. (2022) Identification of Genetic Variation Influencing Metformin Response in a Multi-Ancestry Genome-Wide Association Study in the Diabetes Prevention Program (DPP). *Diabetes*. 10.2337/db22-0702
- [7] Delaneau O, Marchini J, Zagury J-F (2011) A linear complexity phasing method for thousands of genomes. *Nat Methods* 9(2): 179-181. 10.1038/nmeth.1785
- [8] Howie BN, Donnelly P, Marchini J (2009) A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS genetics* 5(6): e1000529. 10.1371/journal.pgen.1000529
- [9] Guindo-Martínez M, Amela R, Bonàs-Guarch S, et al. (2021) The impact of non-additive genetic associations on age-related complex diseases. *Nat Commun* 12(1): 2436. 10.1038/s41467-021-21952-4
- [10] Genomes Project C, Auton A, Brooks LD, et al. (2015) A global reference for human genetic variation. *Nature* 526(7571): 68-74. 10.1038/nature15393
- [11] Dixon WJ (1960) Simplified Estimation from Censored Normal Samples. *Annals of Mathematical Statistics* 31(2): 385-391. 10.1214/aoms/1177705900